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ABSTRACT
HYBRID COMPUTATIONAL TOXICOLOGY MODELS FOR REGULATORY RISK
ASSESSMENT

Prachi Pradeep
Marquette University, 2015
Computational toxicology is the development of quantitative structure activity relationship
(QSAR) models that relate a quantitative measure of chemical structure to a biological effect. In
silico QSAR tools are widely accepted as a faster alternative to time-consuming clinical and
animal testing methods for regulatory risk assessment of xenobiotics used in consumer products.
However, different QSAR tools often make contrasting predictions for a new xenobiotic and may
also vary in their predictive ability for different class of xenobiotics. This makes their use
challenging, especially in regulatory applications, where transparency and interpretation of
predictions play a crucial role in the development of safety assessment decisions. Recent efforts in
computational toxicology involve the use of in vitro data, which enables better insight into the
mode of action of xenobiotics and identification of potential mechanism(s) of toxicity. To ensure
that in silico models are robust and reliable before they can be used for regulatory applications, the
registration, evaluation, authorization and restriction of chemicals (REACH) initiative and the
organization for economic co-operation and development (OECD) have established legislative
guidelines for their validation.
This dissertation addresses the limitations in the use of current QSAR tools for regulatory
risk assessment within REACH/OECD guidelines. The first contribution is an ensemble model that
combines the predictions from four QSAR tools for improving the quality of predictions. The
model presents a novel mechanism to select a desired trade-off between false positive and false
negative predictions. The second contribution is the introduction of quantitative biological activity
relationship (QBAR) models that use mechanistically relevant in vitro data as biological
descriptors for development of computational toxicology models. Two novel applications are
presented that demonstrate that QBAR models can sufficiently predict carcinogenicity when
QSAR model predictions may fail. The third contribution is the development of two novel methods
which explore the synergistic use of structural and biological similarity data for carcinogenicity
prediction. Two applications are presented that demonstrate the feasibility of proposed methods
within REACH/OECD guidelines. These contributions lay the foundation for development of
novel mechanism based in silico tools for mechanistically complex toxic endpoints to successfully
advance the field of computational toxicology.
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CHAPTER 1
INTRODUCTION

Chemical Risk Assessment or evaluation of the extent of toxic effects associated with
xenobiotic exposure is necessary for protection of human or environmental health. Toxicology
is the science that is concerned with the study of adverse effects of chemicals. Conventional
methods of toxicity testing include animal models, which are expensive and time consuming.
This chapter discusses the emergence of computational toxicology models as an alternative to
animal testing. The challenges in the acceptance of computational toxicology models within a
regulatory framework and the major legislative guidelines for their validation are also
introduced.

1.1

Introduction to Toxicology
Xenobiotics are foreign chemicals that are either not found normally in the human body or

not produced naturally. Common xenobiotics include pharmaceutical drugs, environmental
pollutants and pesticides. Every day, we are exposed to a wide variety of xenobiotics that are used
in consumer products, ranging from pharmaceuticals and food additives to agricultural products
and cosmetics. Even though these products are useful, they may be associated with undesirable
side effects in humans as a response to xenobiotic exposure. For example, aspirin (chemical
acetylsalicylic acid) is a relatively safe over-the-counter analgesic that is taken by people all over
the world. However, chronic use of aspirin can cause serious side effects on the gastric mucosa,
and it is fatal at a dose of about 0.2 to 0.5 g/kg [1]. Another example is kohl (black eyeliner), a
commonly used eye cosmetic, that is often contaminated with lead. Absorption of lead or lead
poisoning is considered to be the most important environmental disease and is known to cause
juvenile delinquency, behavioral problems and renal problems [2].
The word “toxicity” describes the extent to which a xenobiotic can cause adverse side
effects. Toxicology is the branch of science that is concerned with the study of adverse or toxic
effects of chemical, physical or biological agents on living organisms and the ecosystem, including
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the prevention and amelioration of such adverse effects [3]. A toxic endpoint is a specific toxic
response to a toxic agent, e.g. skin sensitivity. Toxicity is the leading cause of failure of new
medical devices and pharmaceutical drugs [4, 5]. The success of a medicinal product,
pharmaceutical drug or a medical device depends not only on its efficacy but also on its chemical
composition. Xenobiotic exposure through pharmaceutical drugs happens directly by oral
consumption. Medical devices, on the other hand, cause indirect exposure because of leaching and
migration of chemicals from the device material to the human body. Pharmaceutical drugs and
medical devices, therefore, need to undergo a rigorous regulatory risk assessment procedure before
they obtain marketing approval [6]. Chemical risk assessment or evaluation of the extent of toxic
effects associated with xenobiotic exposure is, therefore, necessary for protection of human and
environmental health.
The extent of risk exerted by a xenobiotic is determined by its absorption, distribution,
metabolism, elimination and toxicological properties, commonly referred to as the ADMET
profile. Absorption is the process of transfer of drug from the site of administration into the
systemic circulation. Distribution is the process of reversible transfer of drug from blood to
different parts of the body and its transportation to the site of action. Xenobiotic distribution is
dependent on several factors like physicochemical properties of the xenobiotic (e.g. solubility),
physiological factors (e.g. permeability of tissue membranes) and xenobiotic interactions in the
blood and tissues (e.g. binding to carrier proteins). Metabolism, also referred to as
biotransformation, is the process of transformation of the xenobiotic inside the body into an easily
excrete-able form. Sometimes it may also involve biochemical transformation of an inactive
xenobiotic into an active metabolite. The process of metabolism usually takes place in the liver.
Elimination is the process of irreversible removal of the xenobiotic and the metabolites from the
body. Elimination can happen by metabolism and excretion [7, 8, 9]. The knowledge of ADME
parameters is useful in predicting xenobiotic concentration in the body at any point of time and its
potential side-effects. It is a fine optimization of a chemical’s potency and its ADMET properties
that ultimately leads to the selection and clinical development of chemical components of a
potential medicinal product. Chemical risk assessment early in the pharmaceutical or device
development is, therefore, important in understanding human biological response to a xenobiotic.
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1.1.1

Sub-disciplines of Toxicology
Toxicology can be broadly categorized into three major sub-disciplines as shown in

Figure 1.1. Each of the sub-disciplines contribute to chemical risk assessment [10, 11].

Figure 1.1: Sub-disciplines of Toxicology.

(1). Mechanistic Toxicology is concerned with understanding how toxic chemicals exert their
adverse effects and how biological systems protect themselves against those adverse effects.
Mechanistic toxicology is based on the principles of cellular and molecular biology for
understanding the underlying biochemical mechanisms behind toxicity. It is a
knowledge-based science in which experimental data are analyzed in answering one or more
of the following questions:
(i). How are xenobiotics absorbed, distributed and metabolized in a biological system?
(ii). How do xenobiotics interact with the cellular system and what are the molecular
mechanisms involved in toxic effects? and
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(iii). How does the biological system respond to a toxic effect?
Thus, mechanistic toxicology deals with the entire ADMET life cycle after xenobiotic
exposure. Mechanistic toxicology is helpful in better understanding of mechanism(s) of
toxicity and in risk assessment of chemicals for human safety.
(2). Descriptive Toxicology is concerned with methods of toxicity testing. Toxicity testing
includes in vivo animal models and in vitro (i.e., bacteria or cultured animal cells ) assays. In
vivo methods span years and involve detection of health effects like functional growth, tumor
development and reproductive disorders. In vitro assays usually span a few hours/days and are
useful in the detection of potential genetic mutations and cellular interactions. Recently,
descriptive toxicology has focused on development of in silico models for predictive
toxicology. In silico models use historical experimental data from in vitro and in vivo
experiments to make predictions of potential toxicity for new and un-tested chemicals. In
silico tools are important for toxicity assessment in the absence of in vitro and in vivo data.
Descriptive toxicology methods can be used to assess the ADMET properties of a xenobiotic.
Descriptive toxicology data is helpful in:
(i). estimating safe levels of chemicals that would not result in a toxic response,
(ii). the issuance of regulatory guidelines concerning allowable levels of xenobiotics in
consumer products,
(iii). understanding mechanisms of toxicity, and
(iv). for the development of mechanistic toxicology.
(3). Regulatory Toxicology is concerned with determination of risk associated with the use of
xenobiotics in consumer products. Such decisions are primarily dependent on mechanistic and
descriptive toxicology data. With this information, safe or allowable levels of xenobiotic
exposure are determined. Regulatory toxicology involves careful analysis of descriptive and
mechanistic toxicology data to arrive at scientific conclusions for regulatory risk assessment.
Regulatory toxicology is practiced by toxicologists serving regulatory agencies such as the US
Food and Drug Administration (FDA) and the US Environmental Protection Agency (EPA).
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These agencies are involved in the laws for regulation and marketing approval of consumer
products.

1.2

Regulatory Risk Assessment
Regulatory risk assessment is the process that ensures marketing of safe and effective

pharmaceutical drugs, medical devices and other consumer products [12]. The main
responsibilities of a regulatory agency are:
(1). Risk assessment and characterization of chemicals for use in consumer products, and
(2). Development of risk management strategies.
Risk assessment of chemicals is based on the results of mechanistic, descriptive and
regulatory toxicology data (Figure 1.2). In simple terms, these responsibilities translate into
answering questions like:
(1). What responses can be defined as “adverse”?
(2). To what extent are consumers exposed to xenobiotics that can cause adverse effects?
(3). How to quantify risk with appropriate consideration of benefits and the criticality of the
adverse outcomes?
Insight from mechanistic, descriptive and regulatory toxicology are used to make
recommendations about safe levels of xenobiotics in consumer products. In addition, several other
factors are also considered in determining risk which include health benefits, availability of
alternatives and the extent of public use. For instance, if a food color is falsely predicted
non-cancer causing it may pass regulatory approval for use in food industry, but will expose the
public to the risk of cancer. Likewise, a pharmaceutical drug that is known to cure depression can
be approved if it causes skin sensitization but not if causes cancer. Thus, risk assessment decisions
are based on the merits of the efficacy and usefulness of products versus the criticality of the side
effects due to xenobiotic exposure.
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Figure 1.2: Risk assessment is based on inputs from all the sub-disciplines of toxicology: mechanistic toxicology, descriptive toxicology and regulatory toxicology.
Regulatory agencies are faced with the challenge of too many existing and new chemicals
to regulate. There are hurdles in the decision making process for risk assessment of new chemicals
since many chemicals do not have mechanistic and descriptive toxicology data. For example, the
incident of crude 4-methylcyclohexanemethanol (MCHM) spill in the Elk river in West Virginia on
January 9, 2014. Elk river is the source of drinking water in nine West Virginia counties. MCMH
is a chemical foam used for washing in coal processing and very little is known about its effects on
human health. The government response, which is based on regulatory recommendations, was
“continue to refrain from using the water for drinking, cooking, cleaning, bathing and washing”
within the spill’s affected areas. Thus, lack of toxicity data for MCMH led to a government
declared state of emergency [13, 14] and restricted water usage. In such unknown situations, when
immediate and critical measures are needed, conventional methods of toxicity assessment
(expensive and time-consuming in vitro/in vivo models) further delay the regulatory process and
cause public alarm.

7

1.3

Computational Toxicology
To circumvent the hurdles outlined in regulatory risk assessment and the need for early

optimization of xenobiotics for use in consumer products, toxicology research focus has shifted
from conventional methods to the development of in silico methods (computational toxicology) for
risk assessment. Conventional methods of toxicity testing, in vivo studies and clinical trials are
performed only after product development and are expensive and time-consuming. Although in
vivo tests are the most accurate methods for identifying the side effects induced by a xenobiotic,
the time and cost associated with them renders them ineffective in reducing the attrition rate
associated with new chemicals and their regulation. It is, also, well known that animal models may
not be the most accurate method to extrapolate the biological response to humans due to evident
physiological differences. Besides, there are also ethical objections in the use of animal models for
toxicity prediction.
Computational toxicology is the computational or in silico prediction of adverse or toxic
effects of chemicals on living organisms. In silico approaches to predictive toxicology focus on
building quantitative structure activity relationship (QSAR) models that can mimic the results of
experimental techniques. In silico methods are appealing because they provide a faster alternative
to otherwise time-consuming laboratory and clinical testing methods [15, 16]. Currently, several
commercial and proprietary in silico QSAR tools are available that can predict toxic effects of a
chemical based on its chemical structure. These tools employ mathematical models and historical
databases of experimental animal data for predicting the toxicity profile of a new
chemical [17, 18]. In silico QSAR tools for toxicology are rapidly evolving and gaining prevalence
for initial estimation of toxic potential for pharmaceutical drugs or chemicals that may be leached
from medical devices.

1.4

Regulatory Applications, Concerns and Guidelines
QSAR models are widely used in the development of new pharmaceutical drugs in the

pharmaceutical industry. They are mainly used for identification or isolation of chemicals that have
a desired biological effect (drug leads) or for early prediction of potential toxic effects. This
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information helps manufacturers in re-engineering the drug leads for achieving the desired
therapeutic effect, ultimately leading to lower chances of product failure due to toxicity and an
increase in the number of safe marketable products. In contrast to industrial use, regulatory
expectations and use of QSAR models are very different. Regulatory agencies foresee greater use
of QSARs in the regulation of existing and new chemicals. Regulatory decisions are primarily
dependent on the short and long term toxicological and clinical effects of xenobiotics. In a
regulatory setting, QSARs can be used to:
(1). Supplement experimental data.
(2). Support prioritization in the absence of experimental data.
(3). Substitute or replace experimental animal testing methods [19, 20].
Regulatory application of QSARs is, therefore, quite opposite in nature as compared to
industrial uses since the chemical in use is known and its biological action is to be predicted to
understand if it may cause any undesired side effects to human or environmental health.
Several QSAR models have been used and validated by US regulatory agencies and are
rapidly gaining impetus in the European Union. Table 1.1 summarizes the different regulatory
bodies and their initiatives and guidelines towards use of in silico predictive tools. To initiate the
regulatory applications of QSARs for drugs, the US Food and Drug Administration (FDA) has
been the actively involved in the development and identification of appropriate in silico QSAR
tools. The FDA Center for Drug Evaluation and Research (CDER) has been using QSAR methods
as a support tool for making regulatory decisions in the absence of experimental toxicology data.
US FDA Critical Path Initiative is particularly aimed at promotion and development of databases
and in silico tools for prediction of toxicity early in the development process to avoid as much risk
to human health. Several in silico tools have been tested by the US FDA Center for Devices and
Radiological Health (CDRH) and CDER under this initiative [21]. The US Environmental
Protection Agency (EPA) is also involved in the testing and development of QSAR models [22].
Estimation Program Interface (EPI) Suite [23] and Toxicity Estimation Software Tool (TEST) [24]
are two freely available in silico tools that have been developed by the EPA.
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Regulatory Agencies

Objectives and Guidelines

(European Union)

Consortium of 34 countries OECD Organization for Economic Co-operation
and Development
(Established 1961)

REACH - Registration, Evaluation, Authorization and Restriction of Chemicals
initiative of European Union
Driven by the requirements for safety
assessment and characterization of old
and new chemicals
(Established 2007)

Danish Environmental Protection Agency
(EPA)

QSAR Principles (2004)
- A defined endpoint
- An unambiguous algorithm
- A defined domain of applicability
- Appropriate measures of goodness-offit, robustness and predictivity
- A mechanistic interpretation, if possible
REACH Principles
- Adequate and appropriate documentation
- The model is scientifically valid
- The chemical of interest falls under the
applicability domain of the model
- The predictions are relevant for risk
regulatory risk assessment
Emphasis on optimization of QSAR
models for false negatives
Danish
QSAR
database
∼160,000 chemicals

houses

(Database established in 2004)
(United States)
US Food and Drug Administration (FDA)
(Established 1906)
US Environmental Protection Agency
(EPA)
Regulation of new industrial chemicals
(Established 1970)

Critical Path Initiative (2004)
- Development of toxicological databases
- Promotion of use of in silico tools

- Estimation Program Interface (EPI)
Suite
- Toxicity Estimation Software Tool
(TEST)

Table 1.1: Regulatory and Legislative Agencies in the European Union and the United States and
their guidelines.
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In the European Union (EU), risk assessment of chemical substances has been mandated
by legislative rulings. The directives include substantial directions on the use of QSARs for
chemical toxicity prediction. The EU REACH (Registration, Evaluation, Authorization and
Restriction of Chemicals) initiative mandates risk assessment of not only new chemicals but also
chemicals which are already in the market [25]. The REACH requirements includes the following
guidelines for the validation of QSAR models to ensure effective regulatory assessment of
chemicals:
(1). the model is scientifically valid,
(2). the chemical of interest falls under the applicability domain of the model,
(3). the predictions are relevant for regulatory risk assessment, and
(4). adequate and appropriate documentation on the model is available [26, 27].
The REACH regulation promotes innovation and development of alternative in silico
testing methods not only for cost benefits but also with ethical considerations in reduction and
eventual replacement of animal models. The Organization for Economic Co-operation and
Development (OECD) which spans 34 countries across the world is a regulatory organization
involved in the assessment of alternative testing methods. Similar to REACH, the OECD also has a
set of following validation principles for the appropriate use of QSAR models for regulatory
applications:
(1). a defined toxic endpoint,
(2). an unambiguous algorithm,
(3). a defined domain of applicability,
(4). appropriate measures of goodness-of-fit, robustness and predictivity, and
(5). a mechanistic interpretation, if possible [28].
The OECD principles are agreed upon internationally for regulatory acceptance of QSAR
models [29].
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REACH Regulations

OECD
Principles

Statistical
Validation

- An unambiguous algorithm
- Appropriate measures of
goodness-of-fit, robustness
and predictivity

- Adequate and appropriate
documentation on the model
is available

Scientific
Explanation

- A defined endpoint
- A defined domain of applicability
- A mechanistic interpretation, if possible

- The model is scientifically
valid
- The chemical of interest
falls under the applicability
domain of the model
- The predictions are relevant for regulatory risk assessment

Table 1.2: Basic principles for the development of QSAR models.

The emphasis on animal welfare and cost-effectiveness make the use of conventional risk
assessment approaches difficult to use. Thus, in the absence of known experimental data and
dependence on time consuming conventional toxicity testing methods regulators are now more
inclined towards using in silico tools to study toxic endpoints for new chemicals [30]. In silico
QSAR tools are the most promising alternative to animal testing approaches towards regulatory
use. However, different QSAR tools often make contrasting predictions for a given chemical and
also vary in their predictive ability for different class of chemicals. The predictive ability of QSAR
tools for different toxic endpoints is an important factor in their use in decision making processes.
QSARs need to be especially optimized for false positives and false negatives for regulatory use as
discussed in Section 1.2. The correct combination of predictive ability for a toxic endpoint,
transparency of predictions, and overall cost and health benefits are important for an in silico tool
to be useful for regulatory risk assessment. Since reliability in predictions is one of the major
concerns in the use of QSARs from a regulatory perspective, the regulatory agencies need to make
sure that a QSAR model is well validated before being used for risk assessment. The OECD
principles and REACH regulations can be sub-categorized to reflect two main considerations in
computational toxicology modeling as shown in Table 1.2. Thus, a robust and reliable in silico
model should be statistically valid and supported by a scientific explanation. The legislative
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guidelines enforced by various regulatory organizations, therefore, ensure that the QSAR models
are robust and reliable before they can be used for regulatory applications.

1.5

Dissertation Contributions
This dissertation seeks to address the concerns outlined in Section 1.4 with the use of

currently available in silico QSAR tools for regulatory risk assessment. The main contributions of
this dissertation are:
(1). An ensemble model that combines predictions from four in silico QSAR tools for improving
the quality of predictions. The model presents a mechanism to select a desired trade-off
between false positive and false negative predictions as desired in regulatory applications.
(2). A novel computational modeling technique Quantitative Biological Activity Relationship
(QBAR) which uses mechanistically relevant in vitro data for development of computational
toxicology models. Two case studies are presented that demonstrate that in vitro data can be
used to develop QBAR models to sufficiently predict carcinogenicity when QSAR tools may
fail.
(3). Two novel methods that explore the synergistic use of structural and biological similarity for
carcinogenicity prediction to develop hybrid QSAR-QBAR models. Two case studies are
presented that demonstrate the feasibility of proposed methods within REACH/OECD
guidelines.
The remainder of this dissertation is organized in four chapters. Chapter 2 reviews the
basic concepts of Quantitative Structure-Activity Relationship (QSAR) models. A regulatory
insight is presented towards the challenges in consideration of in silico QSAR tools as an
alternative to animal testing. The major principles for QSAR validation are briefly discussed
within regulatory guidelines. Chapter 3 discusses the current status of research in the development
of methods to overcome the disadvantages of QSAR models outlined in this introductory chapter.
The chapter presents the details of the method developed in contribution 1. The results and
advantages of the method are discussed within a regulatory framework. Chapter 4 presents a novel
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approach for integrating mechanism based information for the development of QBAR models. The
chapter presents the details of the method developed in contribution 2. Two case studies are
presented to demonstrate the advantages of using in vitro data for the development of QBAR
models for carcinogenicity prediction. The results and advantages of the method are discussed
within a regulatory framework. Chapter 5 discusses the future advances in the field of
computational toxicology within regulatory guidelines. The chapter presents two new methods for
combining QSAR and QBAR modeling techniques for development of hybrid QSAR-QBAR
models developed in contribution 3. The advantages of the proposed methods over existing
methods are demonstrated by two case studies for carcinogenicity prediction. The results and
advantages of the methods are discussed within a regulatory framework. Finally, Chapter 5
presents a summary of the results and the contributions of this dissertation towards the field of
computational toxicology and its significance within a regulatory framework.
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CHAPTER 2
BACKGROUND

Computational toxicology models relating chemical structure to qualitative biological activity
are widely used for the prediction of toxicity of chemicals in the absence of experimental data.
This chapter reviews the principles of chemical structure based computational toxicology
models and the basic concepts of Quantitative Structure Activity Relationships (QSARs). The
current status and use of QSAR tools within regulatory framework and their limitations in
prediction of complex toxicities like mutagenesis and carcinogenesis are discussed. Emerging
methods that make use of mechanistic data for development of computational models are
introduced. Potential benefits of using in vitro data for the prediction of complex toxic
endpoints are discussed.

2.1

Principles of Quantitative Structure Activity Relationships
The backbone of structural similarity based computational toxicology is that the biological

activity of a chemical can be attributed to its structural or chemical properties. Structure activity
relationships can be used to form a hypothesis as to which features of a chemical are required for a
particular biological activity. Hence, similarities between chemicals can be used to predict their
biological activities. A structure activity relationship (SAR) is a qualitative association between a
chemical substructure and the biological effect that a chemical containing the sub-structure may
have. Quantitative structure activity relationship (QSAR) are theoretical models that relate a
quantitative measure of chemical structure (e.g. a physicochemical property) to a physical property
or to a biological effect (e.g. a toxic endpoint). Collectively, SARs and QSARs are referred to as
QSARs [31, 32, 33]. This QSAR based approach can be used to predict biological activities for
untested chemicals as shown in Table 2.1.
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Chemical
1

Chemical
2

Chemical
3

Chemical
4

Chemical
5

Substructure X
(E.g. Benzene ring)

7

3

3

7

3

Activity A

7

3

?

7

3

400 Da

380 Da

420 Da

370 Da

350 Da

3

7

3

?

7

Property Y
(E.g. Molecular weight)
Activity B

Table 2.1: Basic principle behind QSAR modeling.
In Table 2.1, presence of substructure X can be qualitatively related to activity A to form a
SAR relationship. It can be observed that the presence of substructure X is an indication of activity
A. Based on this hypothesis, chemical 3 can be predicted to be be classified as positive (3) for
activity A. Similarly, property Y can be quantitatively related to activity B to develop a QSAR
relationship. It can be observed that chemicals with molecular weight > 400Da are associated
with positive Activity B. Based on this hypothesis, chemical 4 can be classified as negative (7) for
activity A. Thus, such structure activity relationship models can be used to develop predictive
models for chemical toxicity.
Based on the modeling technique, in silico QSAR tools for toxicity prediction can broadly
be classified as:
(1). Expert knowledge based models (SARs), and
(2). Statistical method based models (QSARs)
Expert knowledge based models use rules (structural alerts (SAs)) derived by toxicology
experts who study and interpret the actual structure-toxicological relationships based on datasets of
available toxicological data. These models are reliable since they are based on a true knowledge
base. However, they tend to be more conservative (low sensitivity) in their predictions for new
chemicals when the historical data is limited in size. Expert knowledge based models also suffer
from infrequent updates because of limitations in manual data collection, curation and analysis.
Statistical method based models, on the other hand, use physicochemical features or chemical
similarity methods which can be quantified for toxicity prediction. They require a training data set
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with experimental biological/toxicological data for training the models. Mathematical models are
trained on this data using various machine learning techniques. These models lack expert
knowledge or mechanistic understanding. However, they have the advantage of data mining for
selection of appropriate features and training techniques in addition to error optimization [34, 35].
Table 2.2 presents a summary of the different kinds of in silico QSAR methods, their basic
principle, suitable applications and examples of some tools developed using these methods.

Rule based
expert systems
(SARs)

Statistical model
based systems
(QSARs)

Hybrid systems

Underlying
Algorithm

- Structural Alerts (SAs)
- Expert Judgment

- Mathematical models
- Data Mining
- Machine Learning

- Rule-based
- Statistical modeling

Application

- Less training (chemical) data
- Toxic endpoints with
known mechanism of
action.
E.g. Liver toxicity

- Significant training
(chemical) data
- Toxic endpoints with
little or no knowledge
of mechanism of action
E.g. Carcinogenicity

Combines the best features of rule-based and
statistical methods
- Mechanistic interpretation
- High accuracy

Example

Freely available
- Toxtree
Proprietary
- LHASA Derek

Freely available
- EPA T.E.S.T
- OECD ToolBox
Proprietary
- MultiCASE

Freely available
- VEGA
- Lazar

Table 2.2: Different types of computational toxicology models.

2.2

General Form of QSAR Models
QSAR models can be used to make quantitative predictions of the biological effects of

chemicals. They can also help in understanding how changes in molecular structure can cause
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change in biological properties. QSAR models are mathematical expressions as shown by
Equation 2.1.

Ai = f (D1 , D2 , D3 , ....Dn ),

(2.1)

where Ai are the biological activities expressed as a function of chemical or structural properties
(descriptors) D1 , D2 , D3 , ...Dn [36]. Classical QSAR models used simple linear relationships and
are the pioneer work of Corwin Hansch [37, 33, 38]. In general, QSAR models may be developed
based on three different types of features that can be used as descriptors:
(i) Substructures: A chemical molecule can be represented in terms of known substructures
(fragments). It has been hypothesized that different substructures are independently
responsible for different biological properties. Substructure based QSAR models assume that
these substructures contribute to same biological effect by different chemicals. Given a
chemical compound it can be inspected for the presence of substructures with known
biological activities for predictive modeling.
(ii) Physical Properties: Hydrophobic and electronic properties of chemicals have a profound
effect on its biological properties. Physical properties based QSAR models employ changes
in hydrophobicity and electronic properties to model changes in biological activity. These
properties are measured by solvent-partition coefficients (logP ) and changes in pKa and
redox potential, respectively. LogP is an important descriptor in many QSAR models.
(iii) 3D Properties: Structure-based drug design relies on knowledge of the 3D structure of a
biological target. 3D properties based QSAR models employ molecular properties calculated
from 3D structures for modeling biological activity. Alignment scores is one example of a 3D
property. Alignment scores are obtained by superimposing of new chemical structures on
chemicals with known biological activities.

2.2.1

QSARs for Carcinogenicity
Carcinogenicity is the ability of a chemical to cause or enhance tumor development.

Mutagenicity is the ability of a chemical to cause DNA alterations leading to mutations.
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Mutagenicity is often a precursor to carcinogenicity and, therefore, an important indication of
potential carcinogenicity. Identification of carcinogenic chemicals has been slow and challenging
because of the expensive and time-consuming animal methods.
SAR analysis for carcinogenicity dates back to early 1940s. Polycyclic aromatic
hydrocarbons (PAHs) and aromatic amines are important classes of industrial and environmental
chemicals that are known to be carcinogens and mutagens [39, 40]. The early QSAR studies for
skin carcinogenicity caused by PAHs have shown a correlation between the electron density in the
bay region of the chemicals to their carcinogenic potential ( Figure 2.1). The QSAR equation that
represents this relationship is given by Equation 2.2 [41].

log Iball = 0.55(±0.09) log P − 1.17(±0.14) log(β · 10log P + 1) + 0.39(±0.11)LK
+ 0.47(±0.26)HOM O + 1.93(±2.4). (2.2)

The carcinogenic potential of the PAHs is defined in terms of the Iball index. HOM O is
the energy of the highest occupied molecular orbital. LK is an indicator of substituents at
positions L or K in the PAHs. Presence of substituents (which blocks oxidation) at either of these
positions increases the carcinogenic potential of the chemical.

Figure 2.1: General structure of a polycyclic aromatic hydrocarbon (PAH). Activation to carcinogenic form happens at the Bay region.
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Similar SAR studies for aromatic amines has shown that they are usually oxidized to a
form that leads to DNA modification. The QSAR equation that represents the relationship is given
by Equation 2.3 [41].

log T A98 = 0.65(±0.16) log P + 2.90(±0.59) log(β · 10log P + 1) − 1.38(±0.25)LU M O
+ 1.88(±0.39)I1 − 2.89(±0.81)Ia − 4.15(±0.58). (2.3)

TA98 is the number of revertants (mutations that revert to the normal state) per nmol of the
aromatic amine and is the measure of mutagenic potential of the chemical. LU M O is the energy of
the lowest unoccupied molecular orbital. LU M O suggests that the more readily the chemical can
accept electrons, the higher the value of TA98 or mutagenic potential is. Both the QSARs indicate
how electronic effect is associated with mutagenic/carcinogenic potential of the two class of
chemicals. Similar QSAR relations have also been derived for other classes of carcinogenic
chemicals.

2.3

Development of QSAR models
QSAR model development is a 3-step process. The first step is to generate molecular

descriptors from the chemical structure. Chemicals are represented in terms of their molecular
structure. Several tools are available to calculate molecular descriptors using the structure
representation. The second step is the selection of relevant molecular descriptors. Not all
molecular descriptors play an important role in determining a given biological endpoint. Hence, it
is important to select a group of descriptors that correlate with the structural and physicochemical
properties that are associated with the given biological activity. Once a biological activity and its
associated descriptors are identified, the final step is to obtain a correlation function that can map
the descriptor values to the activity. The ratio of number of descriptors to the size of the training
dataset is an important consideration to avoid over-fitting of the models. Modeling methods like
correlation and pattern recognition are usually employed in the development of quantitative
structure-activity relationships [42, 43].
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2.3.1

Molecular Descriptors
Molecular descriptors are a quantification of the various molecular properties of a

chemical compound. They help in the transformation of some chemical information encoded
within a molecule into a useful number for mathematical purposes. In general there are two kinds
of descriptors (a). 2D descriptors, which are usually physicochemical descriptors and (b). 3D
descriptors, which are usually derived from spatial structures of molecules. Some examples of 2D
descriptors are:
(i) Constitutional Descriptors: They represent properties related to molecular structure, e.g.
molecular weight, total number of atoms in the molecule, number of aromatic rings, etc.
(ii) Electrostatic and Quantum-Chemical Descriptors: They represent properties related to the
electronic nature of the compound, e.g. atomic net and partial charges, solvent accessible
surface area, etc.
(iii) Topological Descriptors: They represent properties which can be inferred by treating the
structure of the compound as a graph, with atoms as vertices and covalent bonds as edges,
e.g. total number of bonds in shortest paths between all pairs of non-hydrogen atoms.
(iv) Geometrical Descriptors: They represent properties related to spatial arrangement of atoms
constituting the compound, e.g. Vander Waals Area.
(v) Fragment based Descriptors: They represent properties related to sub-structural motifs, e.g.
MDL Keys and Molecular Fingerprints.
QSAR relationships can be used to develop in silico tools for the prediction of chemical
toxicity. The ultimate aim is to accurately determine the structural variations that may introduce a
given toxic effect and to be able to suggest compound re-engineering methods to improve overall
potency. An ideal QSAR tool should be able to predict a wide range of toxic endpoints with
sufficient statistical validation. QSAR tools can help in the virtual filtering of chemicals that may
be predicted in having potential toxic effects. QSAR tools are of particular interest in regulatory
settings for toxicity profiling of potential pharmaceutical drugs or chemicals that may be released
from medical devices [30, 19]. A successful predictive QSAR tool can lead to reduction in animal
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testing, clinical trials, and eventual reduction in cost of product development [32, 44, 45]. The
challenge, however, is the development of reliable QSAR tools [46, 47].

2.4

In Silico QSAR Tools for Toxicity Prediction
A number of free and proprietary in silico QSAR tools are available that can predict the

toxicity of a given chemical based on its chemical structure. These tools can be classified as either
expert knowledge-based (SAs), statistical method (QSARs) or a hybrid of the two. Some of the
commonly used in silico tools are OECD QSAR Toolbox [48], Lhasa DEREK [49], EPA
T.E.S.T [24], VEGA [50], Lazar [51], and Toxtree [52]. A brief description of these tools is
presented below:
• OECD QSAR ToolBox is an expert knowledge-based standalone software application. The
new target chemical is profiled into a chemical category based on similarities (e.g. mode of
action or structural similarity) and chosen profiling category. This is used to build the
training data set. The missing toxicological data points are then estimated by
read-across/trend analysis/local QSARs (using local categorized data sets). QSAR toolbox
allows users to use custom databases. It implements the Benigni-Bossa rulebase and OASIS
DNA binding profiler [48].
• LHASA Derek for Windows is an expert knowledge-based system (SAR-based) developed
by Lhasa Ltd. Predictions are based on available data and empirically derived rules from
available toxicological data. The rules cover many biological endpoints, but its main
strengths are prediction of skin sensitization, mutagenicity and carcinogenicity. The training
dataset is obtained from FDA ICSAS/CDER group and FDA CFSAN group. However,
DEREK allows the users to use a custom database, in Derby database format, and alerts.
DEREK makes a prediction only in case of positives and gives no information otherwise.
Once a positive prediction is made, it provides a brief justification of the prediction and cites
the literature references, which provided the structural alerts. Absence of an alert or no
prediction does not necessarily mean that it is a negative prediction; it just means that no
identified alerts were found [53, 49].

22

• EPA Toxicity Estimation Software Tool (T.E.S.T) is an open-source application developed
by the US Environmental Protection Agency (EPA). Prediction is based on five different
QSAR models employing genetic algorithm and regression models. Final output is a
consensus result of the predictions from all the 5 models. The models use the entire database
of training data for making the predictions. It uses the Arena et al. dataset of 293
compounds, which come from FDA/TERIS (Teratogen Information System) [24].
• VEGA is a relatively new effort aimed at providing toxicity predictions to specifically meet
the current EU REACH regulatory demands. VEGA implements the CAESAR and SARpy
models for mutagenicity prediction. It also includes a read across mechanism combined with
QSAR predictions to optimize the confidence [50].
• Lazar (lazy structure-activity relationships) is a statistical-based open-source software
that makes toxicity predictions for various biological endpoints. It is based on identification
of structural fragments (alerts) and also implements statistical machine learning algorithms
for classification. Lazar uses the k-nearest-neighbor approach, while also incorporating
chemical similarities relative to the chosen biological activity [54, 18]. Lazar allows a user
to select the model to be implemented and then creates local QSAR models for the test
chemical. This model uses a different training dataset for different endpoints. Lazar is freely
accessible through an easy to access web implementation and as a standalone application for
Linux [51].
• Toxtree is a hybrid QSAR and knowledge-based open-source software tool which
implements the Benigni-Bossa rulebase and ToxMic rulebase for mutagenicity and
carcinogenicity prediction. Toxtree uses a decision tree framework. Toxtree also allows a
user to implement new rules in the decision tree [52].
• Danish QSAR is a database that houses predictions from different QSAR models for over
166,072 chemicals and can generate specific results due to its Boolean capabilities. The
Danish Environmental Protection Agency (Danish EPA) primarily develops the QSAR
models used and the Joint Research Centre (JRC) in Europe maintains the database [55].
This database uses both in vitro and in vivo models for the predictions. The results are
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derived using the MULTICASE software, which includes eight MULTICASE FDA cancer
models and rodent carcinogenic potency [18].

2.5

Limitations of QSAR Tools
QSAR tools can be used in regulation to supplement experimental data, support

prioritization in the absence of experimental data and as a substitute or replacement for
experimental animal testing methods. In view of these possible uses, regulators often use the
results of more than one QSAR tool. However, different QSAR tools often make contrasting
predictions for a given chemical (e.g.Table 2.3) and also vary in their predictive ability for different
class of chemicals. Often, the validation of a particular QSAR tool and sufficient confidence that it
can be used reliably for a given chemical is not available, which makes handling conflicting
predictions and determining the best prediction difficult [56]. In case of an unknown test chemical
such conflicting predictions are hard to interpret because it is not clear which prediction is the
correct one. These issues make the use of in silico QSAR tools difficult in regulatory risk
assessment since transparency and interpretation of predictions play a crucial role in development
of safety assessment decisions and reports.

Chemical

Toxtree

Lazar

OECD
Toolbox

Danish
QSAR

Biphenyl
(Carcinogen)

7

7

7

7

1,3-Butadiene
(Carcinogen)

7

3

7

3

Crotonaldehyde
(Carcinogen)

7

7

3

3

Chlorodifluoromethane
(Non-carcinogen)

3

7

3

3

1-Phenyl-2-thiourea
(Non-carcinogen)

3

7

3

7

Table 2.3: Misleading carcinogenicity predictions by QSAR tools. The 3 represents carcinogenic
and 7 represent non-carcinogenic predictions, respectively.
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The discrepancy in predictions between different in silico QSAR tools is due to different
molecular descriptors and machine learning algorithms employed for the development of
predictive models. From a regulatory perspective, it is challenging to interpret these results
because: (1). the training datasets are not evident for most QSAR tools, which makes it difficult to
determine if the chemical of interest is adequately represented (structurally) in the training dataset,
and (2). the molecular descriptors are not known, which makes it difficult to provide a mechanistic
explanation for the prediction. Proper structural representation in training datasets and validation
of resultant models are, therefore, important factors in the development of reliable QSAR models
for regulatory applications and characterization of those chemicals for which a reliable prediction
can be made [17, 57, 18].
Mechanistic interpretation of toxicity is a complex phenomenon and it is difficult to
capture all the aspects from a structural similarity perspective. Any in silico QSAR model is a
system that is developed upon known historic data and could be a simplified representation of a
complex phenomenon. QSARs, therefore, have a fair chance to fail in the case of a new untested
chemical. Given the regulatory guidelines for the use of in silico methods, the challenge remains to
better the risk assessment by development of robust in silico models as defined in Chapter 1
Section 1.4. Development of robust in silico methods to overcome the limitations of existing in
silico methods can be achieved in two ways:
1. Development of consensus models that can integrate predictions from multiple tools. Each
tool has its strengths and weaknesses and by leveraging various underlying QSAR models
and training datasets, the resulting consensus prediction should yield more reliable
predictive ability.
2. Development of methods to derive mechanistic information from short term in vitro assay
data for development of computational toxicology models. Most QSAR models suffer from
inherent limitations due to lack of mechanism based selection of molecular descriptors.
Development of new mechanism based methods can overcome the intrinsic deficiencies in
QSAR models.
Both these strategies directly address the statistical validation and scientific validation aspect
of the definition of robust models.

25

2.6

Use of In vitro Data in Computational Toxicology
Recent advances in the field of “omics” technologies (proteomics, metabolomics,

toxicogenomics etc.) offer intriguing avenues for assessing chemical response in in vitro systems.
High-throughput screening methods facilitate the screening of large number of chemicals against a
variety of assays generating substantial in vitro data [58, 59]. The US Environmental Protection
Agency’s (EPA) ToxCast project [60] and the Tox21 consortium of the U.S. EPA , National
Toxicology Program (NTP), National Institutes of Health Chemical Genomics Center (NCGC),
and U.S. Food and Drug Administration (FDA) [61, 62] are two sources of high-throughput in
vitro activity data for thousands of chemicals across several biochemical assays. Innovative
methods can be developed for systematic investigation and integration of these rich and diverse
datasets for advancing the field of computational toxicology.
In vitro methods provide mechanistic insight into cellular response to chemical action. In
vitro data can be utilized in several ways to assist in computational modeling approaches to predict
toxicity as outlined below:
1. In vitro data can offer insight into how different chemicals can alter or perturb certain
biochemical pathways that may result in toxic responses.
2. In vitro data can help in the identification of biological response patterns (biomarkers)
associated with different toxicological endpoints.
3. In vitro data can help in elucidating the mechanism of action involved with various
toxicological endpoints.
Use of in vitro data helps in identifying the underlying cellular and molecular events that
lead from initial exposure to the xenobiotic to the ultimate biological responses. Deeper
understanding of such mechanisms is helpful in extrapolating the data better to humans and
to improve risk assessment of potentially toxic chemicals for human safety.
Based on the benefits outlined above, in vitro data can be used to develop biological
similarity based computational models for toxicity prediction. The underlying concept is based on
the assumption that mechanistically related toxic chemicals will display similar patterns of
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biological activity in various in vitro assays [63, 64]. In vitro data can be used to derive biological
activity relationships between chemicals to develop QSAR like approach as described in
Section 2.1. A collaborative effort between regulators, industry and researchers can lead to the
development of novel mechanism based reliable computational toxicology models suitable for
regulatory risk assessment applications.
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CHAPTER 3
AN ENSEMBLE MODEL OF IN SILICO QSAR TOOLS FOR IMPROVING TOXICITY
PREDICTION

This chapter presents a novel ensemble QSAR model based on a decision tree framework
using Bayesian classification. The model allows for setting a cut-off parameter to select a
desirable trade-off between sensitivity and specificity. The predictive performance of the
ensemble model is compared with four in silico tools (Toxtree, Lazar, OECD Toolbox and
Danish QSAR) for carcinogenicity prediction for a dataset of air toxins (332 chemicals),
medical device leachables (84 chemicals) and a subset of the gold carcinogenic potency
database (480 chemicals). Leave-one-out cross validation results show that after varying the
cut-off, the ensemble model achieves the best trade-off between sensitivity and specificity
(sensitivity: 70.0%, 85.7%, 84.5% and specificity: 91.2%, 91.4%, 77.0%) and highest
inter-rater agreement (kappa(κ): 0.63, 0.76 and 0.62) for the three datasets. The ROC curves
demonstrate the flexible nature of the predictive ability of the ensemble model. This feature
provides an additional control to the regulators in grading a chemical based on the severity of
the toxic endpoint under study.

3.1

Motivation
In silico QSAR tools are gaining wide acceptance as a faster alternative to otherwise

time-consuming clinical and animal testing methods. However, as discussed in Chapter 2, different
in silico tools often make contrasting predictions for a given chemical and may also vary in their
predictive performance across various chemical datasets. In a regulatory context, conflicting
predictions raise interpretation, validation and adequacy concerns. To address these concerns,
ensemble learning techniques in the machine learning paradigm can be used to integrate
predictions from multiple tools. By leveraging various underlying QSAR algorithms and training
datasets, the resulting consensus prediction should yield better overall predictive ability.
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There have been several attempts to investigate methods for combining predictions from
more than one in silico tool to gain better predictive performance. The underlying idea is that each
model brings a different perspective of the complexity of the biological system being modeled and
combining them can amplify their individual capabilities. Zhao et al. developed a hybrid model for
bioconcentration factor (BCF) prediction. They developed and compared different clustering
algorithms (multiple linear regression, radial basis function neural network and support vector
machines) and used those to create hybrid models [65]. Gissi et al. used predictions from two BCF
models implemented in VEGA to arrive at a consensus prediction. They used cut-off rules to arrive
at the most reliable and conservative prediction [66]. In similar efforts for mutagenicity prediction
three different groups (Benignia et al., Ames et al., and Hillebrecht et al.) have evaluated the
predictive performance of four in silico tools (Derek, Leadscope, Multicase and Toxtree) and
compare them with the standard Ames assay. They developed pairwise hybrid models using the
AND (accepting positive results when both tools predict a positive) and OR combinations
(accepting positive results when either one of the tool predicts a positive) [67, 68, 69]. A similar
AND/OR approach has been implemented by Contrera, et al. for the validation and construction of
a hydrid QSAR model using Multicase and MDL-QSAR tools for carcinogenicity prediction in
rodents [70]. The authors extended the work using more tools (Multicase, MDL-QSAR,
BioEpisteme, Leadscope PDM, and Derek). They compared the predictive performance and
constructed hybrid models using majority consensus predictions based on positive predictions from
all four/three/two tools in addition to the AND/OR combinations [71]. The results of all these
studies showed improved overall predictive performance of the hybrid model in comparison to
individual tools.
These efforts indicate that looking at consensus-positive predictions from more than one in
silico QSAR tool had progressively increased the identification of true positives. The studies also
demonstrate that no single QSAR tool performs significantly better than others, and that they also
differ in their predictive ability based upon the toxic endpoint and the chemical datasets under
investigation. However, consensus-positive methods are prone to introducing a conservative nature
in discarding potentially carcinogenic chemicals based on false positive prediction as discussed in
Section 5.1. Therefore, there is a need for a more advanced method of combining predictions from
multiple in silico tools that can address the drawbacks of consensus-positive prediction techniques.
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3.2

Ensemble Machine Learning
The ensemble learning presents a new approach for combining expert QSAR systems. An

ensemble model (classifier) is a unit or a group of multiple independent base classifiers that work
in unison. They are algorithms that can classify unknown data by combining the classification
results of several classifiers in a weighted manner. The strength of an ensemble model depends on
the diversity and predictive ability of the base models. An ensemble model is typically superior in
performance when compared to the base models, which are, therefore, referred to as the weak
models. The reason for the success of ensemble models is that they are built upon a set of diverse
classifiers and implement sophisticated mathematical and statistical machine learning methods to
train the ensembles [72, 73].
Hybrid QSAR models using ensemble approaches have already been developed for
various biological endpoints like cancer classification and prediction of ADMET
properties [74, 75, 76]. However, ensemble learning has not been used for the prediction of
toxicological endpoints. In this study, the Bayes ensemble approach, described in Section 3.3.3, is
investigated for the development of an ensemble model for improving the overall predictive ability
of available in silico tools with special significance in regulatory applications.

3.3

Methods

3.3.1

Datasets
This work uses three datasets for training and validation that consists of both carcinogenic

and non-carcinogenic chemicals. Selection of chemicals in each dataset was based on the
availability of experimental carcinogenicity data and in silico predictions from the tools.
1. Air toxins: A set of 332 chemicals potentially emitted in the industrial environment was
obtained from the Western Australia Department of Health. These chemicals have been
classified into Cramer chemical classes using Toxtree, a software tool released by the
European Chemical Bureau, with the purpose of determining if Cramer class could be used
to assign exposure limits [77]. For this study the Cramer class was not considered, and
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therefore all of the listed chemicals were considered in this analysis. This dataset had a
carcinogen to non-carcinogen ratio of 114:218.
2. Medical device leachables: A set of 84 compounds was obtained from the Center of
Devices and Radiological Health (CDRH) at the US FDA. These chemicals are reported to
be released from medical devices. This dataset had a carcinogen to non-carcinogen ratio of
49:35.
3. Gold carcinogenic potency database (CPDB): The CPDB is a widely accepted reference
containing results from chronic, long-term animal cancer tests on a variety of
chemicals [78]. For this study the database was screened for all compounds with positive or
negative carcinogenic data in mice and/or rats. A positive carcinogenic value was
determined if either species had TD50 data. A non-carcinogenic value was determined if
there was no TD50 value available for that chemical and a negative carcinogenic
experimental result was present. Both male and female results were extracted, where a
positive result of one gender would override a negative of the other. The resultant dataset
consisted of 480 chemicals with a carcinogen to non-carcinogen ratio of 258:222.
The final selection of the datasets was made such that each chemical had experimental data
and predictions from the four in silico QSAR tools. Therefore, identical datasets were used to
analyze the performance of the method.

3.3.2

In Silico QSAR Tools
The true experimental data for these chemicals is obtained from Carcinogenic Potency

Database and Chemical Carcinogenesis Research Information System (CCRIS [79]). Four
open-source in silico tools discussed in Chapter 2 were used to make carcinogenic predictions for
the datasets. The chemicals are searched using unique identifiers CASRN (Chemical Abstracts
Service Registry Number) and structure notation SMILES (simplified molecular-input line-entry
system). If the CAS and/or SMILES code was not given in the dataset, Chemspider or TOXNET
was used to retrieve that data [80, 81]. Any positive mutagenic result was recorded as a positive
prediction for carcinogenicity for the test chemical.
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1. OECD ToolBox: All chemical identities based on the CAS number of the test chemical
were searched for this analysis. The chemicals were screened for two mutagenic and two
carcinogenic profiling alerts: in vitro mutagenicity alerts by ISS (Ames mutagenicity), in
vivo mutagenicity alerts by ISS (Micronucleus assay), carcinogenic (genotoxic and
non-genotoxic) alerts by ISS, and oncology primary classifications. A positive result in a
profiling category for any chemical identity was considered a positive result for the target
chemical. If the CAS number was not found in the OECD input search or if profiling
resulted in no predictions (all results were not applicable) then the chemical was removed
from the final training dataset.
2. Danish QSAR: Chemicals were searched in the database using the CAS number for
mutagenicity, mutagenicity in vivo, and carcinogenicity. The Ames sub tests under
mutagenicity were only recorded if the Ames test (salmonella) was positive, as
recommended by the database. One positive or equivalent prediction in any category was
recorded as a positive prediction for the test chemical.
3. Lazar (lazy structure-activity relationships): Chemicals were queried in the tool using the
simplified molecular-input line-entry system (SMILES) using the web interface established
in 2010. The DSSTox carcinogenic potency DBS multicellcall endpoint was used to
represent the carcinogenic predictions for the target compounds. In addition, the two
available mutagenic endpoints were also analyzed: DSSTox carcinogenic potency DBS
mutagenicity and Kazius-Bursi Salmonella mutagenicity. A positive result for either
category was recorded as a positive prediction for the test chemical.
4. Toxtree: Chemicals were queried in the Toxtree 2.5.0. using the SMILES code using the
Benigni/Bossa Rulebase (for mutagenicity and carcinogenicity). If a potential carcinogenic
alert based on QSAR models or if any structural alert for genotoxic and non-genotoxic
carcinogenicity were reported then the prediction was recorded as a positive prediction for
the test chemical.
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3.3.3

Bayes Ensemble Model
The Bayes ensemble model is based on prior probabilities and is statistically

robust [82, 83]. The model uses training data for classification by estimating uncertain quantities
using the Bayes theorem. Bayes theorem uses the training data as evidence (E) for a seen outcome
(O) to construct a probability for predicting the outcome when the evidence is seen in the
future [84]. The probability of seeing the outcome in the past (training dataset) is termed as the
prior probability (P (E|O)) and the probability of predicting the outcome occuring in the future is
termed as the posterior probability (P (O|E)). The Bayes theorem calculates the posterior
probability by Equation 3.1.

P (O|E) =

P (E|O)P (O)
,
P (E)

(3.1)

where P (O) is the probability of the outcome and P (E) is the probability of the evidence. In a
binary classification problem, the final predicted outcome is the one with a higher value of
P (O|E) as determined by Equation 3.2.

ω = arg max P (Ok |E).
k{1,2}

(3.2)

In case of ensemble modeling for classifying new chemicals, the training data consist of
predictions from n in silico tools and true experimental class about the nature of the chemical
(toxic/non-toxic). Each tool can predict the class, ω, as 1 or 0 representing toxic and non-toxic,
respectively. Since there are n in silico tools, the total number of prediction combinations possible
is k = 2n . The vector sk represents each unique prediction combination from the in silico tools.
For example, if a chemical is analyzed by four tools and the predictions are 0 (Tool 1), 1 (Tool 2), 0
(Tool 3), 0 (Tool 4) then the prediction combination vector sk = {0, 1, 0, 0}. From a Bayesian
perspective, prediction combination from each tool is the evidence and class is the outcome. The
Bayes theorem computes the posterior probability of a chemical being toxic (ω = 1) or non-toxic

33

(ω = 0) associated with each combination of predictions from the tools, P (ω|s = sk ) using
Equation 3.3.

P (ω|s = sk )k =

P (sk |ω)P (ω)
,
P (sk )

(3.3)

where, sk is the combination of prediction by the tools for the test chemical, P (sk |ω) is the prior
probability of observing a prediction combination sk given that a chemical is toxic or non-toxic,
P (ω) is the probability of a chemical being toxic or non-toxic and P (sk ) is the probability of a
particular prediction combination from the in silico tools. For each prediction combination sk there
is an associated posterior probability. Since the toxicity prediction problem is binary in nature, i.e.
the classification is either toxic (ω = 1) or non-toxic (ω = 0) the final estimate of the prediction,
ω 0 , given by the Bayes ensemble model is the one with the greater value of P (ω|s = sk ). This
means that a new test chemical is classified as toxic or non-toxic based on all tested chemicals that
resulted in sk . The decision is, therefore, based on available information of previously tested
chemicals, which makes it different from a consensus rule.

3.3.4

Algorithm
The Bayes ensemble model as described in Section 3.3.3 was implemented within a

decision tree framework. A decision tree is a support tool that uses a top down tree like approach
for arriving at a decision. Each node in the tree represents a decision and each branch represents
the outcome leading to the final decision. A path from root to leaf represent a classification
rule [82]. In our approach, each decision tree path translated into a combination of prediction by
the different tools. The decision leaf represented the posterior probability of being carcinogenic as
associated with each combination as shown in the decision tree. The estimate for final
classification (ω 0 ) was done in two steps.
• Step 1: Four tools were used to predict the carcinogenic ability of the chemicals for all the
three datasets leading to k = 16 prediction combinations. The predictions were recorded as
1 and 0, (representing carcinogenic and non-carcinogenic, respectively) and used to
construct a decision table as shown in Table 3.1 for each data set.
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Combination
Number

Tool 1

Tool 2

Tool 3

Tool 4

Posterior
Probability

s1

0

0

0

0

P (ω|s = s1 )

s2

0

0

0

1

P (ω|s = s2 )

s3

0

0

1

0

P (ω|s = s3 )

s4

0

0

1

1

P (ω|s = s4 )

s5

0

1

0

0

P (ω|s = s5 )

s6

0

1

0

1

P (ω|s = s6 )

s7

0

1

1

0

P (ω|s = s7 )

s8

0

1

0

1

P (ω|s = s8 )

s9

0

1

1

1

P (ω|s = s9 )

s10

1

0

0

0

P (ω|s = s10 )

s11

1

0

0

1

P (ω|s = s11 )

s12

1

0

1

0

P (ω|s = s12 )

s13

1

0

1

1

P (ω|s = s13 )

s14

1

1

0

0

P (ω|s = s14 )

s15

1

1

0

1

P (ω|s = s15 )

s16

1

1

1

1

P (ω|s = s16 )

Table 3.1: Prediction combination table with posterior probability for each combination number.
Each combination number represents a prediction combination from each of the four QSAR tools.

The posterior probability of a test chemical being toxic for each prediction combination was
calculated from Equation 3.2 as:

P (ω = 1|s = sk ) =

P (sk |ω = 1)P (ω = 1)
,
P (sk )

(3.4)
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where
N(ω=1,sk )
,
Nω=1
N(ω=1)
P (ω = 1) =
, and
N
Nsk
P (sk ) =
.
N

P (sk |ω = 1) =

(3.5)
(3.6)
(3.7)

So
(
P (ω = 1|s = sk ) =
=

N(ω=1,sk ) N(ω=1)
N(ω=1) )( N )
Ns
( Nk )

N(ω=1,sk )
,
Nsk

(3.8)
(3.9)

where Nsk was the number of chemicals with a prediction combination sk in the training
dataset, N(ω=1) was the total number of carcinogens in the training dataset, N(ω=1,sk ) was
the number of carcinogens with prediction combination sk , and N was the total number of
chemicals in the training dataset.
• Step 2: The tools were used to make a prediction for the test chemical, which were then used
to determine the test chemical’s prediction combination vector sk . The combination sk was
then used to look up the posterior probability P (ω = 1|s = sk ) or Pk associated with it from
the decision table. The final prediction (ω 0 ) for a new chemical was estimated based on the
value of Pk , which was compared to a variable cut-off and a decision was made using the
framework outlined in Figure 3.1. In a classic binary classification problem, the value of the
cut-off is fixed to 0.5, as explained in Section 3.3.3. However, the choice of 0.5 as a cut-off
may not be the best to address the concerns with the use of QSAR tools for a regulatory
application, as explained in Section 3.1. There needs to be more flexibility in arriving at a
consensus decision and, hence, also in the selection of the cut-off.

In the Bayes ensemble model, the value of the cut-off can be varied leading to different
decision points for the final classification. Since it is a probability measure, the cut-off can range
from 0 to 1. The Bayes ensemble model is very powerful in giving the user the option of varying
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Figure 3.1: Decision tree based Bayesian classifier ensemble for determining carcinogenicity. The
posterior probability, Pk , as determined from Table 3.1 is compared with a variable cut-off which
can be varied between 0 and 1.
the cut-off to reach the desired level of sensitivity and specificity as demonstrated in Section 3.4.3.
The flexibility in changing the cut-off also makes the model endpoint independent and can be used
for the prediction of any toxic endpoint of interest.

3.3.5

Model Validation
One of the major concerns with the use of QSAR tools for a regulatory applications is the

reliability in their predictions. QSARs need to be assessed for their scientific validity so that
regulatory organizations have a sound scientific basis for decision making. As mentioned in
Section 3.1, the OECD member countries agreed upon a set of principles as guidelines for
scientifically validating a QSAR model. These principles require that a model (i). has a defined
endpoint, (ii). has an unambiguous algorithm, (iii). has a defined domain of applicability, (iv). has
appropriate measures of goodness-of-fit, robustness and predictability, and (v). has a mechanistic
interpretation, if possible. The fourth principle ensures that a QSAR model is robust and can make
reliable predictions for a well-defined endpoint.
In accordance with these guidelines, external model validation was performed and a range
of model statistics were calculated for a comprehensive performance analysis. Leave one out cross
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validation (LOOCV) technique was used for external validation where N models were developed
each with (N − 1) chemicals as training set and 1 chemical as the test set. The following standard
metrics were then calculated to assess performance assessment of the models:

TP
,
TP + FN
TN
,
Specif icity =
TN + FP
TP + TN
Accuracy =
,
TP + FN + TN + FP
TP
PPV =
, and
TP + FP
TN
,
NPV =
TN + FN
Sensitivity =

(3.10)
(3.11)
(3.12)
(3.13)
(3.14)

where TP is the number of true positives, TN is the number true negatives, FP is the number of
false positives, and FN is the number of false negatives reported in the tests. Accuracy or
concordance is a measure of correctness of overall predictions. Sensitivity is a measure of
correctness in prediction of positives or toxic chemicals and specificity is a measure of correctness
in prediction of negatives or non-toxic chemicals. Positive predictive value (PPV) is the proportion
of positives or toxic chemicals that are correctly predicted and negative predictive value (NPV) is
the proportion of negatives or non-toxic chemicals that are correctly predicted. High sensitivity or
low false negatives is especially important under REACH requirements as discussed in Section 5.1.
PPV and NPV are crucial in understanding the predictive power of the models based on the
representation of toxic and non-toxic chemicals in the training datasets.
The OECD guidelines also emphasize on appropriate measures of goodness-of-fit,
robustness and predictivity of QSAR models. Several reports discuss the potential techniques for
internal and external measure of model validation [85, 86, 87]. Therefore, in addition to the
standard metrics following two conceptually simpler statistical parameters are suggested, which
are indicative of overall concordance and performance of each model as compared to chance and
each other:
1. Cohen’s Kappa (κ): The Kappa coefficient is a measure of pairwise inter-rater agreement or
specific agreement compared to a chance agreement. Thus, it can be used as a measure of
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agreement between the test results and the true results, and also for comparing the
performance of different tools with respect to one another. It is calculated as below:

κ=

P +T N )(F N +T N )
(T P + T N ) − ( (T P +F N )(T P +F P )+(F
)
N
P +T N )(F N +T N )
1 − ( (T P +F N )(T P +F P )+(F
)
N

.

(3.15)

In this study, the Kappa coefficient is used to compare how well the predictions from various
tools agree with the experimental or true values. Values of κ=0, 0.41 < κ < 0.60,
0.61 < κ < 0.80 and κ=1 represent no, moderate, substantial and perfect agreement,
respectively [88, 89].
2. Receiver Operating Characteristics (ROC) Curve: A ROC curve is a plot of true positive
rate (sensitivity) and the false positive rate (1 - specificity). ROC curve demonstrates how
the performance of a binary classifier changes as the threshold parameters are varied [90].
Area under the ROC curve can be used to compare the classification tools; higher area
implies a better the classification. As seen in Figure 3.2, an ideal predictor is one which
minimizes false positives and maximizes true positives. In this application, ROC curves can
be used to select the optimal cut-off in by selecting a trade-off between desired sensitivity
and specificity as demonstrated in Section 3.4.3.

3.4
3.4.1

Results and Discussion
Accuracy, Sensitivity and Specificity
Statistical performance of the ensemble model in comparison to the various in silico tools

is summarized in Tables 3.2, 3.3 and 3.4. The statistics for the Bayes ensemble model are
presented for three different cut-offs, which demonstrate the utility of the cut-off feature. As
shown, the accuracy of the Bayes ensemble model was the highest and always greater than 80%.
REACH legislatives emphasize on the reduction of false negatives and improvement in specificity
by the ensemble model is indicative of that. The specificity was highly improved as compared to
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Figure 3.2: Reciever Operating Characteristic (ROC) plot. The top left point on the curve denotes
an ideal predictor and the red dotted line denotes a random predictor.
the in silico tools and was as high as 91.43% for the medical devices dataset. PPV and NPV values
were also significantly improved and were higher than 80% for all the three datasets.

Model

Accuracy
(%)

Sensitivity
(%)

Specificity
(%)

PPV (%)

NPV (%)

Toxtree

75.56

68.18

79.51

64.10

82.32

Lazar

75.24

74.55

75.61

62.12

84.70

Danish
QSAR

74.29

80.91

70.73

59.73

87.35

OECD
Toolbox

76.19

69.09

80.00

64.96

82.83

Bayes Ensemble
(Cut-Off=0.4)

83.81

70.00

91.22

81.05

85.00

Bayes Ensemble
(Cut-Off=0.5)

83.81

70.00

91.22

81.05

85.00

Bayes Ensemble
(Cut-Off=0.6)

82.22

65.45

91.22

80.00

83.11

Table 3.2: Performance metrics for air toxins dataset. The highest value for each metric is highlighted in red.
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Varying the cut-off leads to a minor change in accuracy but helps in achieving a balance
between sensitivity and specificity. It can be noted that for the air toxins dataset, Lazar had the best
predictions amongst the in silico tools. However, the Bayes ensemble model improved the overall
accuracy, PPV, NPV and also boosted the specificity while maintaining similar sensitivity. The
statistics also demonstrated the inability of any particular in silico tool of consistent predictions
across different chemical datasets. The ensemble model demonstrated consistency in the nature of
predictions across all the three datasets. This performance can be attributed to the sophisticated
nature of the machine learning algorithm for training the models.

Model

Accuracy
(%)

Sensitivity
(%)

Specificity
(%)

PPV (%)

NPV (%)

Toxtree

61.91

57.14

68.57

71.80

53.33

Lazar

85.71

85.71

85.71

89.36

81.08

Danish
QSAR

71.73

83.67

54.29

71.93

70.37

OECD
Toolbox

60.71

57.14

65.71

70.00

52.27

Bayes Ensemble
(Cut-Off=0.4)

88.10

85.71

91.43

93.33

82.05

Bayes Ensemble
(Cut-Off=0.5)

88.10

85.71

91.43

93.33

82.05

Bayes Ensemble
(Cut-Off=0.6)

88.10

85.71

91.43

93.33

82.05

Table 3.3: Performance metrics for medical device leachables dataset. The highest value for each
metric is highlighted in red.

3.4.2

Cohen’s Kappa coefficient
Cohen’s Kappa coefficient (κ) values for all the in silico tools and the Bayes Combiner

model are presented in Table 3.5. For all the three datasets, the Bayes ensemble model has the best
Kappa coefficient which means that the Bayes ensemble predictions concur with the experimental
data the best. Toxtree, Danish QSAR and OECD Toolbox demostrate less than moderate
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Model

Accuracy
(%)

Sensitivity
(%)

Specificity
(%)

PPV (%)

NPV (%)

Toxtree

66.04

84.50

44.59

63.93

71.22

Lazar

80.63

86.05

74.32

79.57

82.09

Danish
QSAR

65.00

91.09

34.68

61.84

77.00

OECD
Toolbox

64.79

84.50

41.89

62.82

69.93

Bayes Ensemble
(Cut-Off=0.4)

81.04

83.33

75.23

80.14

82.27

Bayes Ensemble
(Cut-Off=0.5)

80.21

84.50

75.23

79.85

80.68

Bayes Ensemble
(Cut-Off=0.6)

80.42

84.50

77.03

80.83

79.91

Table 3.4: Performance metrics for the CPDB dataset. The highest value for each metric is highlighted in red.
agreement with the experimental values for all the datasets. Lazar has better but variable
agreement and depends on the chemical dataset under study. Interestingly, the Bayes ensemble
model with a cut-off of 0.4 has a κ > 0.62 in all the three datasets. It is an indication of stronger
and more substantial agreement with the experimental values as compared to the other tools.

3.4.3

ROC Curve
Figure 3.3 shows the receiver operating characteristics plot for all the in silico tools and

the Bayes ensemble model. An ideal binary predictor would have zero false predictions and so the
desired point on the ROC curve is top left corner where sensitivity is one and (1-specificity) is
zero. The black line corresponds to the performance of a random classifier which does not have
any preferences in a binary outcomes. The higher the area under the ROC curve, the greater is the
predictive ability of the model.
The tools give a binary prediction, therefore, they are represented as a point on the ROC
plot. In case of Bayes ensemble model, a curve can be traced for each sensitivity-specificity

42

Model

Air Toxins

Device
Leachables

CPDB

Toxtree

0.47

0.25

0.30

Lazar

0.48

0.71

0.61

Danish QSAR

0.48

0.39

0.27

OECD Toolbox

0.48

0.22

0.27

Bayes Ensemble
(Cut-Off=0.4)

0.63

0.76

0.62

Bayes Ensemble
(Cut-Off=0.5)

0.63

0.76

0.60

Bayes Ensemble
(Cut-Off=0.6)

0.59

0.76

0.61

Table 3.5: Cohen’s kappa coefficient (κ). The highest value for each dataset are highlighted in red.
combination obtained after changing the value of the cut-off as explained in Section3.3.4. In this
study, the cut-off is varied between 0 and 1 with a step size of 0.1 allowing for 11 decision points
for model validation. Hence, the ROC plot consists of data points corresponding to each value of
cut-off which can be traced to obtain a ROC curve. The ROC curve for the Bayes ensemble model
is higher than all the other tools implying better quality of predictions.
The variable cut-off in the ROC curve can be adjusted to select a trade-off between
sensitivity and specificity. This feature provides an additional control to the regulating agencies in
grading a chemical based on the severity of the toxic endpoint under study. It exhibits user-control
and flexibility in the predictive ability of the ensemble model. For example, as seen in Table 3.6
the final predictions for the chemicals in Chapter 2, Table 2.3 can be adjusted by selection of the
cut-off in the Bayes ensemble model: (i). Carcinogen bi-phenyl (CAS 92-52-4) which is a widely
used fungicide and pesticide is predicted as non-carcinogenic by all the four tools (Toxtree, Lazar,
OECD Toolbox and Danish QSAR). However, a cut-off = 0 in the Bayes ensemble model
classifies it as carcinogenic, (ii). Carcinogen 1,3-butadiene (CAS 106-99-0) is often found as a
contaminant in cosmetics. It is predicted carcinogenic by two tools (Toxtree and OECD Toolbox)
and non-carcinogenic by two tools (Lazar and Danish QSAR). However, a cut-off ≤ 0.6 in the
Bayes ensemble model classifies it as carcinogenic, (iii). Carcinogen crotonaldehyde (CAS
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(a) Air Toxin Dataset

(b) Medical Device Leachables Dataset
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(c) CPDB Dataset

Figure 3.3: Receiver operator characteristics (ROC) curve of Bayes ensemble model as compared
to other QSAR tools. The Bayes classification at different cut-off’s is depicted by green points. The
black line depicts a random classifier.
123-73-9) is predicted as carcinogenic by two tools (OECD Toolbox and Danish QSAR) and
non-carcinogenic by two tools (Toxtree and Lazar). However, a cut-off ≤ 0.6 in the Bayes
ensemble model classifies it as carcinogenic, (iv). Non-carcinogen chlorodifluoromethane (CAS
75-45-6) is predicted as carcinogenic by three tools (Toxtree, Danish QSAR and OECD toolbox).
However, a cut-off ≥ 0.4 in the Bayes ensemble model classifies it as non-carcinogenic, and (iv).
Non-carcinogen 1-phenyl-2-thiourea (CAS 103-85-5) is predicted carcinogenic by two tools
(Toxtree and OECD Toolbox) and non-carcinogenic by two tools (Lazar and Danish QSAR).
However, a cut-off ≥ 0.3 in the Bayes ensemble model classifies it as non-carcinogenic.
Overall, the results show that the Bayes ensemble model is better and more consistent with
respect to different in silico tools, which makes it compatible with regulatory usage. The model
combines predictions from various in silico tools in a transparent and reproducible manner. It can
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Chemical

Toxtree

Lazar

OECD
Toolbox

Danish
QSAR

Bayes Ensemble
(Cut-off)

Biphenyl
(Carcinogen)

7

7

7

7

3 (= 0)
7 (≥ 0.1)

1,3-Butadiene
(Carcinogen)

7

3

7

3

3 (≤ 0.6)
7 (≥ 0.7)

Crotonaldehyde
(Carcinogen)

7

7

3

3

3 (≤ 0.2)
7 (≥ 0.3)

Chlorodifluoromethane
(Non-carcinogen)

3

7

3

3

3 (≤ 0.3)
7 (≥ 0.4)

1-Phenyl-2-thiourea
(Non-carcinogen)

3

7

3

7

3 (≤ 0.2)
7 (≥ 0.3)

Table 3.6: Final Bayes ensemble predictions by varying the cut-off for each chemical. The 3
represents carcinogenic and 7 represent non-carcinogenic predictions, respectively.
also be optimized to reduce the number of false predictions while maintaining flexibility in
addressing other considerations in making these predictions.

3.5

Conclusion
The results of this study demonstrate that different in silico tools vary in the quality of

predictions depending on the underlying QSAR model and chemical datasets used. The Bayes
ensemble model presented here is consistent in its performance across all the three datasets. The
results specifically show improved (i). accuracy of predictions, (ii). specificity and positive
predictive value, which are an indication of reduction in false positives, and (iii). Kappa
coefficient, across all datasets. The statistics demonstrate how ensemble machine learning methods
can be used to increase the capability of consensus QSAR models for toxicity prediction.
Additionally, as seen, the ensemble model offers flexibility in making the predictions as needed.
The Bayes ensemble model shows how in silico QSAR tools with different complexity and
accuracy can be used together for development of more reliable predictors. The results suggest that
ensemble modeling techniques are a good strategy for refining hybrid models and to tailor their use
based on the severity and concerns associated with the toxic endpoint under study. An example
application was presented with Toxtree, Lazar, OECD Toolbox, and Danish QSAR, and three
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different classes of chemical datasets for carcinogenicity prediction. However, this approach can
be extended to different tools and different kinds and sizes of chemical datasets for different
toxicological endpoints as well.
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CHAPTER 4
USE OF IN VITRO DATA TO DEVELOP QUANTITATIVE BIOLOGICAL ACTIVITY
RELATIONSHIP (QBAR) MODELS FOR CARCINOGENICITY PREDICTION

Several studies have demonstrated that the predictive power of in vitro data based
computational models does not significantly differ from that of the chemical descriptors based
Quantitative Structure Activity Relationship (QSAR) models. This chapter proposes the use of
mechanistically relevant in vitro assay data in identification of relevant biological descriptors
and development of QBAR models for carcinogenicity prediction. The chapter demonstrates
how mechanistically relevant in vitro data can be used to develop QBAR models for in vivo
carcinogenicity prediction via two case studies, supported by theory and application. The
results demonstrate the similarities between QBAR and QSAR modeling in: (i). the selection
of relevant descriptors to be used in different machine learning algorithm, and (ii). the
development of a computational model that maps chemical/biological descriptors to a toxic
endpoint. Both case studies show increased sensitivity or lower rates of false negatives, which
is desirable in regulatory applications. Such mechanism based models may be used to develop
and advance computational strategies for regulatory risk assessment.

4.1

Introduction
Chemical Risk Assessment or evaluation of the extent of toxic effects associated with

chemical exposure is necessary for protection of human or environmental health. Computational
toxicology is the in silico prediction of adverse or toxic effects of chemicals on living organisms.
In silico models provide a less expensive, faster and more efficient alternative to otherwise
time-consuming conventional animal and clinical testing methods. Quantitative Structure Activity
Relationship (QSAR) models are the most widely used alternative to conventional animal and
laboratory testing. They are theoretical models that relate a quantitative measure of chemical
structure to a physical property or a biological effect. QSAR model development is a 3-step
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process: (i). generation of molecular descriptors, (ii). selection of relevant molecular descriptors,
and (iii). statistical mapping of the descriptors to the toxic endpoint under consideration [45, 32].
QSAR models have been continuously improving with new machine learning algorithms,
molecular descriptors and training databases [43, 91, 92]. However, several studies show that they
are still not very predictive for mechanistically complex endpoints like carcinogenicity [17, 18].
These limitations are primarily due to multiple mechanisms of action associated with more
complex toxicological endpoints. Furthermore, the OECD principles for QSAR model
development emphasize on mechanistic interpretation of results (if possible) in addition to
appropriate measures of goodness-of-fit, robustness and predictability [28, 25, 26]. Mechanistic
interpretation of toxicity is complex and it is difficult to capture all the aspects of toxicity from a
structural perspective. Development of new mechanism based methods and a paradigm shift
towards a systems biology based approach towards toxicology is, therefore, a necessity in the
future development of computational toxicology.

4.2

Quantitative Biological Activity Relationships
Recent trends in high-throughput screening methods facilitate the screening of large

number of chemicals against a variety of in vitro assays. The availability of in vitro datasets
enables better insight into the mode of action of chemicals and better identification of potential
mechanism(s) of toxicity. Thus, in vitro datasets provide intriguing avenues for using biological
similarity in computational modeling for toxicity prediction. Quantitative Biological Activity
Relationships (QBAR) can, thus, be defined as theoretical models that relate a quantitative measure
of biological similarity to a toxicological effect. The underlying principle behind QBAR models is
that chemicals with similar biological responses are likely to have similar toxicological effects.
Several studies have demonstrated the use of in vitro data in the development of predictive
QBAR models for in vivo toxicology [93, 94, 95, 96, 97]. The results of these studies for
carcinogenicity prediction show that all high-throughput assays do not contribute equally as
predictors of in vivo carcinogenicity. The report on carcinogenicity prediction trials by the U.S.
National Toxicology Program (NTP) states that carcinogenicity is generally a poorly predicted
endpoint and makes a guideline that best models tend to be those that integrate biological
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mechanism-based data [98]. This recommendation aligns with the OECD principles for use of
QSAR models in regulation, which includes a mechanistic interpretation (if possible) among other
criteria for model validation [28, 25]. Based on these reports, the use of specific in vitro assay data
is suggested in identification of relevant biological descriptors and development of QBAR models
for carcinogenicity prediction. It is demonstrated how in vitro data can be used independently to
develop predictive models for in vivo carcinogenicity via two case studies. The case study in
section 4.3.1 demonstrates how to select relevant in vitro assays as biological descriptors for
development of QBAR models (analogous to selection of relevant chemical descriptors for QSAR
modeling). The case study in section 4.3.2 demonstrates how different in vitro assays for selected
endpoints can be used together as biological descriptors for development of a QBAR model
(analogous to statistical mapping of chemical descriptors to a toxic endpoint in QSAR modeling).

4.3
4.3.1

Case Studies
Identification of a Novel Biological Descriptor Based on Xenobiotic Induced
Cytochrome P450 Transcription for Carcinogenicity Prediction

4.3.1.1

Cytochrome P450 Enzyme System
Cytochrome P450 (CYP) enzymes are the most important enzymes in the metabolism

process in mammals and are primarily responsible for the metabolism (degradation and
elimination) of xenobiotics [99]. CYP enzymes are subdivided into various families based on the
percentage of amino acid sequence identity. The major families are CYP1, CYP2 (with five
subfamilies CYP2A-E), and CYP3. There are about 57 identified CYP enzymes that are found to
be involved in metabolism reactions. Approximately 75% of the drugs are metabolized by P450s.
Out of those, five major isoforms viz., CYP2D6, CYP3A4, CYP2C9, CYP2C19 and CYP1A2 are
involved in about 75 − 90% metabolic reactions. CYP2D6 alone is involved in the metabolism of
about 70% of marketed drugs [99, 100, 101].
Xenobiotic metabolizing enzymes can help in detoxification by elimination of potential
carcinogens or facilitate toxicity by conversion of primary non-carcinogens (procarcinogens) into
secondary carcinogenic metabolites. Procarcinogens usually require transformation into a more
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electrophilic from to cause DNA damage and cancer. Thus, they can be classified into two
categories. The first class includes enzymes that are more involved in drug metabolism, such as
CYP2A6, CYP2B6, CYP2C9, CYP2C19 and CYP2D6. The second class includes CYP1A1,
CYP1A2, CYP2E1 and CYP3A4, which are found to be involved in the metabolism of
procarcinogens. Significant effort has been spent in characterization of the mechanism of
activation of procarcinogens and toxicants by P450 enzymes [102, 103].

4.3.1.2

Cytochrome P450 Induction and Carcinogenicity
Cytochrome P450 enzymes are either expressed constitutively in fixed amounts or induced

by certain substrates. Induction is usually a protective mechanism and helps in detoxification, but
can also lead to an increase in production of carcinogenic, mutagenic and/or cytotoxic
metabolites [104]. Several clinical studies have shown significantly increased or decreased levels
of certain P450s in tumor tissue versus normal tissue suggesting a relationship between CYP
induction and tumor development.
Polycyclic aromatic hydrocarbons (PAHs) are known carcinogens, which are distributed
everywhere in the environment [105]. PAHs are usually metabolized by CYP1A1 and CYP1B1
enzymes. Many studies have demonstrated that CYP1As are highly inducible by carcinogenic
(PAHs) [106]. Such feedback cycle enables the PAHs to induce their own metabolism into
carcinogenic forms. CYP1B1 has been found to be expressed at abnormally high levels (122 out of
127) tumors under investigation. It is the most expressed form of CYP1 family in breast cancer
tissue. CYP1B1 is hypothesized to be involved in tumor growth and progression [107, 108].
CYP1B1 bears ∼ 40% homology with both CYP1A1 and CYP1A2 enzymes. CYP3A enzymes
play an important role in catalysing the metabolism of different drugs, carcinogens and
endogenous substances.
Variation in expression of different P450 enzymes leads to significant changes in
carcinogenic response. Notable agreement has been seen between the Ames test for genotoxicity
and ENACT enzyme induction assay; and they seem to align with the potential carcinogenicity of
test chemicals. Induction of CYP enzymes has been hypothesized to be associated with potential
toxicity and tumor occurrences at certain sites [109, 110]. The observation of such prominent
induction of P450 enzymes by the PAHs and their increased expression in tumor tissue raises
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concerns for the safety of humans and animals in general. The impact of these studies led to
profound influence on the drug development, cancer research, and toxicology. Pharmaceutical
companies employ a general policy in the drug development process to discontinue drug
development if the drug shows CYP1 inducibility, for fear of possible toxic or carcinogenic
effects [111].
P450 enzymes that are involved in procarcinogen activation and metabolism are
reasonably well conserved in their expression among different species. Therefore, P450 enzyme
induction can serve as a system for analyzing the interrelations between induction of drug
metabolism and chemical toxicity in general. In this chapter, the role of simultaneous induction of
three P450 enzymes is investigated for the identification of carcinogens.

4.3.1.3

Methods

• In vitro Assay Data
Cellzdirect enzyme induction data for CYP1A1, CYP1A2 and CYP3A4 were obtained from
the phase I of U.S. EPA’s ToxCast database [60, 112]. CellzDirect assay reports fold-change
in expression (above basal levels) of the enzymes in an in vitro test after exposure to
chemicals for 6, 24, and 48 hrs. The data set consists of 320 chemicals across the three
enzymes. Chemicals that had fold-change data for all three enzymes for 6hr (dataset 1) and
24hr (dataset 2) time points and experimental carcinogenicity data were selected for this
study. This filtering reduced the number of chemicals to 17 in dataset 1 and 16 in dataset 2.
• Carcinogenicity Data
The experimental in vivo carcinogenicity data for test chemicals was obtained from
publically available carcinogenic potency database (CPDB) [78] and chemical
carcinogenesis research information system (CCRIS) [79]. The distribution of carcinogens
to non-carcinogens is 4:13 for dataset 1 and 8:8 for dataset 2.
• Chemical Diversity
Diversity of the chemical dataset is an important measure for model validation and
robustness. Diversity of chemicals in the two datasets was evaluated by the AP Tanimoto
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coefficient. Tanimoto coefficient ranges between 0 and 1, where 0 indicates completely
dissimilar and 1 indicates completely similar. Chemicals with a Tanimoto coefficient of 0.7
and greater are considered biologically similar molecules [113]. Figure 4.1 shows a
distribution of chemicals with respect to each other. The chemicals in both the datasets are
structurally diverse as seen in the heatmap.

• Machine Learning Algorithm: Support Vector Machines (SVM)
SVM is a supervised machine learning algorithm used in classification and regression
analysis. It is a binary classifier that calculates an optimal hyper plane for categorizing data,
which consist of pairs of values (xi , yi ) : i = 1, .., n, where xi is the data point with k
features (fj : j = 1, .., k) and yi is the corresponding class label. A linear hyper plane
separates all data points of one class from those of the other class and is used to classify any
new data points [82, 114]. SVM models are especially suited for this problem because they
were originally designed for training data with small size and binary classifiers.
Svmtrain [115], a Matlab SVM implementation was used for this analysis. The svmtrain
function was used with default parameters and the linear kernel function. Fold-change in
expression of CYP450 enzymes is used as features in model classification and the actual
experimental value is used as the class label. A new chemical with enzyme induction data
can be classified using the svmclassify function based on the hyper plane generated using the
training data set as explained in Section 4.3.1.4.
• Model Validation
External model validation using leave one out cross validation (LOOCV) was performed. N
SVM models were developed each with (N − 1) chemicals as the training set and 1
chemical as the test set. The following standard metrics were then calculated for the
performance assessment of the model:
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(a) Dataset 1 (n=17)

(b) Dataset 2 (n=16)

Figure 4.1: HeatMap representation of the chemical diversity of the two datasets measured in terms
of Tanimoto distance. The annotations in each cell correspond to the distance between the two
chemicals (numbers). The colorbar on the right shows mapping of the distance (range: 0-1) to a
gray colorscale.
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where TP is the number of true positives, TN is the number of true negatives, FP is the
number of false positives and FN is the number of false negatives reported in the tests.
Accuracy or concordance is a measure of correctness of overall predictions. Sensitivity is a
measure of correctness in prediction of positives or carcinogenic chemicals and specificity is
a measure of correctness in prediction of negatives or non-carcinogenic chemicals.
Receiver Operating Characteristics (ROC) which is a plot of true positive rate (sensitivity)
versus false positive rate (1 - specificity) was also developed. The ROC plot demonstrates
how the performance of a binary classifier changes as the threshold parameters are
varied [90].
• Performance Comparison with In-Silico Tools
The performance of the SVM classifier is compared with three standard in silico QSAR tools
viz., Toxtree (expert knowledge-based) [52], OECD Toolbox (statistical) [48] and Vega
(hybrid) [50]. The tools make a binary prediction about carcinogenic potential of the test
chemicals.

4.3.1.4

Results
The SVM separates the two classes (carcinogens and non-carcinogens) by generating a

hyper plane for each training dataset in the LOOCV analysis. Figure 4.2 is an example
representation of how the SVM separates the two classes (carcinogens and non-carcinogens) by a
hyperplane. A new test chemical is evaluated based on the fold-change in the expression of
CYP1A1, CYP1A2 and CYP3A4 and classified as carcinogenic or non-carcinogenic depending
upon its distance from the separating hyperplane.
Statistical performance of the SVM classifier in comparison to the various in silico tools is
summarized in Table 4.1. As shown, the accuracy was greater than 80% for both the datasets.
Sensitivity and specificity were also improved as compared to the in silico tools. The results are
more relevant for dataset 2, which is more balanced with an equal distribution of carcinogens and
non-carcinogens.
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(a) Dataset 1 (n=17)

(b) Dataset 2 (n=16)

Figure 4.2: Support vector classification: visualization of the classification hyperplane.
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Model

Accuracy
(%)

Sensitivity
(%)

Specificity
(%)

Dataset 1 (n=17)
Toxtree

64.7

100.0

53.9

Vega

82.4

50.0

92.3

OECD Toolbox

52.9

100.0

38.5

SVM Classifier

88.2

75.0

92.3

Dataset 2 (n=16)
Toxtree

56.3

50.0

62.5

Vega

43.8

12.5

75.0

OECD Toolbox

62.5

62.5

50.0

SVM Classifier

81.3

87.5

75.0

Table 4.1: Performance metrics for SVM classification as compared to in silico tools. The highest
value for each metric is highlighted in red.
Figure 4.3 shows the receiver operating characteristics of the SVM classifier with
reference to the QSAR tools. An ideal binary predictor would have zero false predictions and so
the desired point on the ROC plot is top left corner where sensitivity is one and (1-specificity) is
zero. The black line corresponds to the performance of a random classifier which does not have
any preferences in a binary outcomes. Since the predictions were binary in nature, each classifier
was represented as a point on the ROC plot. The closer the prediction is to the ideal point, the
greater is the predictive ability of the classifier. As seen, SVM classifier offers better trade-off
between sensitivity and specificity and out performs the QSAR tools for both the datasets.

4.3.1.5

Discussion
The SVM classification QBAR model suggests a relationship between carcinogenic

potential and the ability of test chemicals to simultaneously induce transcription of CYP1A1,
CYP1A2 and CYP3A4 enzymes. The ROC curve demonstrated a better trade-off between
sensitivity and specificity in SVM classification versus in silico tools used. SVM classification also
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(a) Dataset 1 (n=17)

(b) Dataset 2 (n=16)

Figure 4.3: ROC plot of SVM classification, Toxtree, Vega and OECD Toolbox based on leave one
out cross-validation. The black line depicts a random classifier.
had better performance metrics than in silico QSAR tools demonstrating the advantage of using
biological data as descriptors for predictive modeling.
Figure 4.1 shows how structurally diverse the chemical datasets are with reference to
Tanimoto similarity index. It is interesting to observe that even with such a diverse dataset there is
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an apparent correlation between chemical carcinogenicity and the ability to simultaneously induce
the three enzymes. This demonstrates that even without structural similarity toxicological response
can be predicted based on biological similarity. This observation validates the concept behind
QBAR modeling. The findings illustrate that xenobiotic induced cytochrome P450 expression (in
vitro data) can be successfully used as a descriptor in QBAR modeling for carcinogenicity
prediction.

4.3.2
4.3.2.1

QBAR Model of In vitro Genotoxicity Assays for Carcinogenicity Prediction
Carcinogenicity, Mutagenicity and In vitro Genotoxicity Assays
Carcinogenic chemicals can be broadly categorized as genotoxic and non-genotoxic

carcinogens based on their mechanism of action. Genotoxic carcinogens exert their carcinogenic
ability by direct damage or alteration of the DNA. Mutagenic toxicity is the ability of a physical or
chemical agent to cause mutations by damage to the DNA [116, 117]. Owing to the correlations
between mutagenicity and carcinogenicity, mutagenic toxicity is widely used as an indicator of
possible carcinogenicity. Short term in vitro mutagenicity tests are, therefore, widely used to assess
genotoxic carcinogenicity [118].
Experimentally, mutagenicity is routinely assessed by the Ames test, which is an in vitro
bacterial reverse mutation assay to test genotoxicity [68]. The Ames test is a benchmark method
for mutagenicity testing by virtue of its well established standard protocol and acceptance within
the regulatory agencies. Over the past decades, several other bacterial mutagenicity tests have been
developed that are now being used worldwide because of their concordance with the Ames test. In
vitro genotoxicity assays are gaining importance because they: (i) present themselves as a short
term and an effective alternative to long term in vivo rodent cancer studies, (ii). offer an insight
into the mechanism behind genotoxic mode of action of chemicals, and (iii). can be used in the
quantification of risk associated with genotoxic chemicals [119, 120].
Unlike genotoxic carcinogens, there is no clear understanding of the mechanism of action
of non-genotoxic carcinogens. Carcinogenesis by non-genotoxic carcinogens can occur due to
chronic cell injury, immunosuppression, increased secretion of trophic hormones, receptor
activation, or CYP450 induction [116, 121]. Given the complex nature of non-genotoxic
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carcinogenicity, the results of in vitro genotoxicity assays are not sufficient and could well be
over-conservative and mechanistically unjustifiable. For instance, negative result in the Ames test
cannot necessarily be translated into a negative result for carcinogenicity, which leads to increased
false negative predictions. The National Toxicology Programme (NTP) conducted a study on the
ability of the Ames test to predict carcinogenicity and reported good accuracy but low sensitivity
(∼ 45%). The Ames test is also reported to have ∼ 85% reproducibility rate and ∼ 70%
concordance with structural alerts for carcinogenicity [67].
In general, in vitro genotoxicity assays are reported to have low sensitivity for prediction
of carcinogenicity. The use of genotoxicity testing strategy for carcinogenicity prediction, thus,
comes with a caveat of misleading false positive and false negative predictions. The latter case of
false negatives is especially important under REACH regulations for regulatory acceptance of
computational toxicology models [26]. It is clear that the performance of different assays varies
quite widely and, therefore, no single test should be considered as a gold standard for
carcinogenicity prediction. A stepwise approach using a battery of in vitro genotoxicity assays
should be performed to overcome the weaknesses of a single test [122, 123, 124]. It is proposed
that this protocol be adjusted to mathematically combine the results of different genotoxicity
assays to arrive at a final prediction. Such a combination is expected to improve the sensitivity and
overall concordance while still preserving the mechanistic insight from each of the in vitro assays.
In this chapter, in vitro genotoxicity assay data were used as biological descriptors for
carcinogenicity prediction as a proof-of-concept for development of proposed QBAR models.

4.3.2.2

Methods

• In vitro Genotoxicity Assay Data
The European Centre for the Validation of Alternative Methods (ECVAM), released a list of
22 genotoxic and 42 non-genotoxic chemicals for the evaluation of the ability of various in
vitro tests to predict rodent carcinogenicity. The results of 9 high-throughput in vitro
genotoxicity assays (Ames, micronucleus, H2AXISV, Vitotox, Radarscreen, RAD51,
Cystatin, p53, Nrf2 [125, 126, 127]) were collected from open literature for the ECVAM set
to develop a QBAR model for carcinogenicity prediction.
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• Carcinogenicity Data
The experimental in vivo carcinogenicity data for test chemicals was obtained from publicly
available carcinogenic potency database (CPDB) [78] and chemical carcinogenesis research
information system (CCRIS [79]). Chemicals with both chemical in vivo carcinogenicity
and in vitro assay data were finally selected for classification analysis. This filtering led to a
total of 56 chemicals in the dataset. The distribution of carcinogens to non-carcinogens in
the dataset is 31:25.
• Machine Learning Algorithm: Random Forests (RF)
Random Forest classification is a machine-learning algorithm that produces an ensemble of
unpruned decision trees for classification [128]. Each tree is developed by (i). selecting a
bootstrap sample from the training data with replacement, (ii). randomly selecting the best
descriptor variables at each node and growing the tree, and then (iii). estimating the
classification error by testing the tree on the remaining data. The new data is classified based
on the majority prediction of all the trees in the ensemble. The implementation is relatively
simple since only two parameters need to be specified: the number of trees in the forest and
the number of predictor variables at each node. The number of trees is generally
proportional to the number of predictor variables, so that each predictor is likely enough to
be selected. The number of predictor variables is generally defaulted to the square root of the
total number of variables [129, 130, 131].
The RF algorithm is especially suited for this problem because: (i). the algorithm can assess
the importance of different predictor variables (in vitro assays) and selects them accordingly
at different decision nodes incorporating multiple modes of action, (ii). it does an internal
performance assessment on the left out training data, thus, strengthening the analysis, and
(iii). it is robust against over-fitting. In general, the error rate (strength) of a RF depends
upon the correlation between the trees and the strength of the trees. Higher correlation leads
to increased error rates and higher strength of the each tree leads to decreased error
rates [132, 133].
Treebagger [134], the RF implementation in Matlab, was used in this analysis. The
Treebagger algorithm uses bagging to develop an ensemble of decision trees for
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classification. There is no recommended threshold for the number of trees and usually the
number is varied to observe any performance changes. Based on different articles on using
RFs, the number of trees was varied between 5 and 500 and default values for other
parameters were used.

4.3.2.3

Results
External model validation using leave one out cross validation (LOOCV) technique was

performed and the metrics defined in section 4.3.1.3 were evaluated. Table 4.2 summarizes the
correlation analysis of in vitro genotoxicity assays to rodent carcinogenicity tests. The benchmark
Ames assay had a sensitivity of about 49% whereas the H2AXIS assay had the highest overall
accuracy or concordance of about 70%. In general, all the genotoxicity assays had high specificity
but low sensitivity (< 52%) for the given ECVAM dataset.
The corresponding statistics for RF classification results are summarized in table 4.3.
Similar to reports in a study [135] that increasing the number of trees did not lead to improved
prediction accuracy. The best classification metrics were obtained at generating only 5 trees. RF
classification with 5 trees improved the sensitivity to about 61%.

Accuracy
(%)

Sensitivity
(%)

Specificity
(%)

Ames

67.86

45.16

96.00

MN

64.29

41.94

92.00

H2AXISV

69.94

51.61

92.00

Vitotox

64.29

41.94

92.00

Radarscreen

62.50

45.16

84.00

RAD51

60.71

35.48

92.00

Cystatin A

66.07

41.94

96.00

P53

66.07

48.39

88.00

Nrf2

62.50

54.84

72.00

In vitro Assay

Table 4.2: Performance metrics of genotoxicity assays. The highest value for each metric is highlighted in red.
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Number
Trees

of

5

10

20

30

40

50

Accuracy(%)

67.86

62.50

62.50

58.93

58.93

64.29

Sensitivity(%)

61.29

51.62

58.06

54.84

54.84

58.06

Specificity(%)

76.00

76.00

68.00

64.00

64.00

72.00

100

110

120

130

140

150

Accuracy(%)

58.93

58.93

62.50

58.93

62.50

62.50

Sensitivity(%)

54.84

54.84

58.07

54.84

54.84

54.84

Specificity(%)

64.00

64.00

68.00

64.00

72.00

72.00

200

300

400

500

600

700

Accuracy(%)

62.50

58.93

60.71

62.50

64.29

64.29

Sensitivity(%)

54.84

51.61

54.84

54.84

58.07

58.07

Specificity(%)

72.00

68.00

68.00

72.00

72.00

72.00

Number
Trees

Number
Trees

of

of

Table 4.3: Performance metrics of the in vitro data based RF classifier (QBAR model) with varying
number of trees. The highest value for each metric is highlighted in red which is obtained for a
Random Forest with 5 trees.
Figure 4.4 shows the receiver operating characteristics of the RF classifiers with reference
to the in vitro assays. The red line corresponds to the performance of a random classifier that does
not have any preferences in a binary outcomes. As seen, RF classifiers had higher sensitivity as
compared to the genotoxicity assays and showed improved rate of false negatives.

4.3.2.4

Discussion
The results of the example case study demonstrate that RF classification addresses the

issue of low sensitivity of in vitro genotoxicity assays as discussed in Section 5.4.2. High
sensitivity is especially important under REACH requirements for regulatory applications i.e., to
protect environment and human health. Gain in sensitivity happens at the expense of specificity or
higher rate of false positives which also affects the overall accuracy. It is important for a classifier
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Figure 4.4: ROC plot of RF classification and in vitro genotoxicity assays based on leave one out
cross-validation. The black line depicts a random classifier.
to have high sensitivity in order to reduce the number of false negatives. RF classification does not
result in any improvement in overall accuracy but it still maintains the accuracy of the best in vitro
assay with the additional benefit of lower number of false positives. In terms of genotoxicity
assays, false negatives most likely include non-genotoxic carcinogens [118]. Thus, improved
sensitivity is probably an indication of higher rate of identification of non-genotoxic carcinogens
using genotoxicity assays.
The results of the RF classification also illustrate that: (i). the threshold parameter in the
model (number of trees in the random forest) can be changed to adjust the desired trade-off
between false positives and false negatives. However, if any in vitro assay were to be used
independently, there is no reference or protocol to change the threshold for each new chemical, and
(ii). the choice of number of trees in RF implementation creates only minor variation in the
classifier performance which demonstrates the robustness and consistency in performance of RF
algorithm for development of classification models. The results demonstrate how RF classification
results based on combination of in vitro genotoxicity assays can improve the identification of true
carcinogens. Further analysis can also be done to identify the most important assays to assist in the
design and selection of an in vitro battery of genotoxicity tests for improved carcinogenicity
prediction.

64

4.4

Conclusion
The availability of high-throughput in vitro assay data offers a unique opportunity of

deriving knowledge about a chemical’s mechanism of toxic action. Mechanistically relevant in
vitro assays can be used as a powerful tool for identification of biomarkers of chemical toxicity and
uncover novel biochemical pathways underlying complex toxicological endpoints.
This chapter proposed the use of specific in vitro assays data in identification of relevant
biological descriptors and development of QBAR models for carcinogenicity prediction. The main
objective of the approach is to demonstrate a strategy for development of quantitative biological
activity relationship models with carcinogenicity as an example endpoint. Two case studies
supported by theory are presented to highlight similarities between QBAR and QSAR modeling
techniques. Case study in section 4.3.1 and 4.3.2 demonstrate an analogy between QSAR and
QBAR modeling in: (i). the selection of relevant descriptors to be used in different machine
learning algorithm, and (ii). the development of a computational model which maps
chemical/biological descriptors to a toxic endpoint, respectively. Both the case studies show
increased sensitivity or lower rates of false negatives, which is desirable in regulatory applications
and are suppoted with theory to address the OECD/REACH regulations for scientific validation as
well.
The results show that in vitro data can be sufficiently used to develop QBAR models for
carcinogenicity prediction. Such mechanism based models can be used along with QSAR models
for mechanistically complex toxicological endpoints to successfully advance the development of
toxicology and risk assessment studies.
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CHAPTER 5
HYBRID QSAR-QBAR MODELS FOR TOXICITY PREDICTION
Chemical structure based computational models (QSARs) have limitations in prediction of
complex toxic endpoints. Biological similarity based computational models (QBARs) have
limitations in extrapolation of in vitro responses to in vivo responses. Combination of
structural and biological features for development of predictive models for in vivo toxicity has
practical applications under REACH and OECD requirements for regulatory risk assessment.
This chapter proposes two novel techniques for the development of hybrid QSAR-QBAR
models. The methods satisfy the requirement for adequate and mechanistically reliable
interpretation of predictions as they are developed using both structural and biological
similarity. Two case studies are included which demonstrate the utility and the advantage of
the proposed methods over existing QSAR and QBAR methods.

5.1

Introduction
The primary responsibility of regulatory toxicologists is the estimation of safe levels of

chemical concentrations in marketable consumer products for protection of human and
environmental health. This risk assessment process is largely based on mechanistic and descriptive
toxicology data for the test chemical. However, the is challenge is regulation of too many
chemicals especially with an increasing surge of chemicals that are being used in various consumer
products and/or are released into the environment. Presently, up to 80,000 chemicals already exist
in the market and notifications for about 2000 new pre-manufacture chemicals happen every year.
Driven by the requirements for safety assessment and characterization of old and new chemicals
the REACH initiative of the European Union (EU) foresees increased use of alternative (in silico)
methods for reduction in time, cost and number of animals associated with conventional animal
testing methods [20, 27, 136, 137]. Alternative testing strategies are particularly useful in
regulatory applications because that information can be used to: (i). supplement experimental data,
(ii). support prioritization in the absence of experimental data, (ii). speed up the regulatory
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decision making process, and (iv). eventually substitute or replace experimental animal testing
methods [15, 16, 34].
In silico techniques for predictive toxicology primarily involve development of
quantitative structure activity relationship (QSAR) models, which are theoretical models that relate
a quantitative measure of chemical structure to a physical property, or a biological effect.
Traditional QSAR models employ chemical structure data as numerical descriptors, representing
inherent chemical properties, in a machine learning algorithm for toxicological classification of
chemicals. QSAR models have been used to develop in silico tools, which are widely used in the
pharmaceutical industry and regulatory agencies for drug discovery, risk assessment, toxicity
prediction and regulatory decisions [45, 32, 43]. However, as discussed in Chapter 3 and 4, QSAR
models often have limitations in their predictive ability due to: (i). lack of proper chemical
coverage in the training datasets, (ii). conflicting predictions by different QSAR models, and (iii).
the inability to capture the complex mechanisms associated with certain toxic endpoints.
More recently, a paradigm shift is seen in the ideology behind computational modeling for
toxicity prediction. There has been increased emphasis on the design and development of targeted
in vitro assays for screening and characterization of chemicals [56, 138]. The availability of
high-throughput screening methods has allowed for rapid generation of chemical response data
across a number of in vitro assays. Chapter 4 discusses novel applications of selected in vitro assay
data in identification of relevant biological descriptors and development of quantitative biological
activity relationship (QBAR) models for toxicity prediction. In vitro data has also been used as
biological descriptors in conjunction with chemical structural descriptors for development of
hybrid QSAR-QBAR models for predictive toxicology [94, 95, 97, 139], as discussed in Chapter 4.
Incorporation of in vitro data and development of QBAR models addresses some of the limitations
of QSAR models by virtue of their inherent mechanism based approach to predictive toxicology.
However, there are challenges in the use of in vitro data for predictive toxicology due to: (i).
experimental variability leading to poor quality data, (ii). questionable extrapolation of in vitro
responses to human effects, and (iii). the identification of relevant assays for a particular toxic
endpoint to unravel novel mechanistic networks.
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5.2

Hybrid QSAR-QBAR models
QSAR models are especially suited for development of predictive models for

mechanistically simple toxic endpoints when significant training (chemical) data is available.
QBAR models, on the other hand, are especially suited for development of predictive models for
more complex toxic endpoints even with smaller training (chemical) data. Integration of both
modeling techniques to develop hybrid QSAR-QBAR models not only benefits from their
complementary predictive insights but also alleviates the limitations associated with both of
them [93, 59, 96].
Hybrid QSAR-QBAR models can be realized based on two standard strategies for
integration techniques as shown in Figure 5.1. Type 1 models are developed as consensus models
that combine responses from multiple models. The simplest approach for type 1 models is the
majority voting technique where the class with the maximum number of votes is the preferred
class. Type 2 models are developed using a pool of mixed physico-chemical and biological
descriptors. Type 2 models can be more sophisticated in nature since they allow the
implementation of novel techniques in selection of relevant descriptors and a wide range of
machine learning algorithms for model development. Most of the studies reporting hybrid
QSAR-QBAR models implement standard machine learning algorithms using a combination of
physico-chemical and biological descriptors in a brute force manner [94, 95, 97, 139]. Such
approaches are not very progressive since they are limited by the lack of : (i). a well defined
approach for the selection of relevant descriptors, and (ii) transparency in the relative weightage
and contribution of the two modeling techniques. Newer strategies that utilize the idea of chemical
similarity in addition to mixed structural and biological descriptors for hybrid QSAR-QBAR
model development have been reported in two recent studies [140, 141].
This chapter proposes novel strategies for development type 1 and type 2 hybrid
QSAR-QBAR models. Two case studies are presented for each type which demonstrate their
application in the development of predictive models for in vivo carcinogenicity. Case study in
section 5.3.2 demonstrates how chemical response data from relevant in vitro assays and
predictions from multiple QSAR models can be combined together using weighted average
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(a) Type 1

(b) Type 2

Figure 5.1: Hybrid QSAR-QBAR models.
ensemble learning method to develop a type 1 QSAR-QBAR model. Case study in section 5.4.2
demonstrates how structural similarity measured in terms of Tanimoto coefficient can be combined
with in vitro genotoxicity assay data to develop a type2 QSAR-QBAR model.

5.3

A Novel Strategy for Development of a Type 1 Hybrid
QSAR-QBAR Model

5.3.1

Weighted Averaging Ensemble Algorithm
Ensemble learning algorithms are techniques for development of consensus models.

Ensemble modeling techniques are based on the principle that integration of several diverse
classifiers enhances the performance of the final classifier. Furthermore, the method retains the
valuable information provided by all the classifiers. Herein, a novel application of the weighted
averaging ensemble classifier technique is presented for combining the results of multiple QSAR
and QBAR based models. Weighted averaging is similar to simple averaging, except that each
classifier is assigned a weight (significance) based on its individual predictive accuracy. The
weight assigned to each classifier is calculated as follows:
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Wi =

Ai
,
1 − Ai

(5.1)

where Ai is the predictive accuracy and Wi is the weight of the ith classifier and is calculated as:

Ai =

T Pi + T Ni
,
T Pi + F Ni + T Ni + F Pi

(5.2)

where T Pi is true positives, T Ni is true negatives, F Pi is false positives and F Ni is false
negatives reported by the ith classifier. The final weighted classification of the model, Classf inal ,
is then calculated as:

Classf inal

P
Ci ∗ W i
= P
,
Wi

(5.3)

where Ci is the class (0 or 1 i.e., non-toxic or toxic, respectively) predicted by the ith classifier.
Classf inal takes a value between 0 and 1, and is assigned a class based on the boundary cut-off.

5.3.2

Case Study: Using Weighted Averaging Algorithm for Combining in silico
QSAR Tools and in vitro Assay Data to Develop a Hybrid QSAR-QBAR
Model for in vivo Carcinogenicity Prediction

• Dataset
The European Centre for the Validation of Alternative Methods (ECVAM), released a list of
22 genotoxic and 42 non-genotoxic chemicals for the evaluation of the ability of various in
vitro tests to predict rodent carcinogenicity. The results of two high-throughput in vitro
genotoxicity assays, viz., Ames and micronucleus, were collected from open literature for
this dataset [125, 126, 127]. Two in silico QSAR tools, Toxtree and Lazar, were used to
predict carcinogenicity for this dataset. The corresponding in vivo rodent carcinogenicity
information was obtained from publicly available carcinogenic potency database
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(CPDB) [78] and chemical carcinogenesis research information system (CCRIS [79]). The
final dataset consists of a total of 56 chemicals with the ratio of carcinogens to
non-carcinogens of 31:25. Thus, four methods were used to make predictions about the
carcinogenic potential of the ECVAM dataset and were used as the individual classifiers in
the weighted majority model.
• Results
Leave one out cross validation was used to make a weighted prediction for each chemical in
the dataset. Table 5.1 shows the performance metrics of the in silico (QSAR) tools and the in
vitro (QBAR) assays. Table 5.2 shows the performance metrics of the weighted majority
model with varying cut-off values.

Toxtree

Lazar

Ames

MN

Accuracy(%)

69.23

76.92

61.54

57.69

Sensitivity(%)

78.57

64.29

35.71

28.57

Specificity(%)

58.33

91.67

91.67

91.67

Table 5.1: Performance metrics for in silico tools (QSAR) and in vitro assays (QBAR). The highest
value for each metric is highlighted in red.

Hybrid QSAR-QBAR Weighted Average Model
(Cut-off)

(0.0)

(0.1),
(0.2)

(0.3)

(0.4)

(0.5),
(0.6)

(0.7),
(0.8)

(0.9),
(1.0)

Accuracy(%)

53.85

76.92

76.92

69.23

69.23

61.54

57.69

Sensitivity(%)

100.00

92.86

71.43

57.14

50.00

35.71

21.43

Specificity(%)

0.00

58.33

83.33

83.33

91.67

91.67

100.00

Table 5.2: Performance metrics for hybrid QSAR-QBAR model with varying cut-off. The highest
value for each metric is highlighted in red.
Note: Cut-off values of 0.1 and 0.2, 0.5 and 0.6, 0.7 and 0.8, and 0.9 and 1.0 yield the same result.
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Figure 5.2: Receiver Operating Characteristic plot comparing the performance of the Random Forest classification with the in vitro genotoxicity assays. Blue line depicts a random classifier.
Figure 5.2 shows ROC plot which demonstrates the the relative performance of the
individual classifiers and the weighted majority model with regards to sensitivity and
specificity. The value of the cut-off can be varied between 0 and 1 to achieve a desired level
of trade-off between sensitivity and specificity. The best performance is obtained at a cut-off
of 0.1 and 0.2 which boosts the sensitivity to 92.86%. However, a more balanced
performance is obtained at a cut-off of 0.3 as seen in the ROC plot.
• Discussion
The main feature of the weighted algorithm is that it does not assume any classifier to be
superior than others. The relative power is decided on the basis of their individual predictive
ability. Every classifier employs a different strategy for making a prediction of the true class
and averaging the classifiers may produce a better approximation of the true class. This
study shows that classifiers with diverse predictive ability can be combined together to
improve the overall sensitivity, which is desirable under REACH requirements for the use of
alternative methods of toxicity testing in regulatory applications. The example demonstrates
the applicability of the technique for carcinogenicity prediction. However, the method can
be extended to include more number of classifiers and other toxicological endpoints too.
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5.4

A Novel Strategy for Development of a Type 2 Hybrid
QSAR-QBAR Model

5.4.1

Classifier Selection Algorithm
High-throughput screening data have mostly been used as independent descriptors along

with physiochemical properties for development of type 2 hybrid QSAR-QBAR models. Herein, a
novel classifier selection method is proposed which considers multiple in vitro assays as
independent classifiers and then selects a classifier that is most competent in a local training space
for making the final classification. The proposed method first defines a local training dataset for
each chemical taking into account structural similarity of chemicals and then selects a classifier
using a selection criteria based on local efficiency. The following three steps characterize the
work-flow of this approach:
1. Selection of the local training dataset: The structural similarity score of each test chemical
from the remaining chemicals in the chemical dataset is determined. Similarity is measured
in terms of the Tanimoto coefficient and the scores are obtained from the structure clustering
option on Pubchem (https://pubchem.ncbi.nlm.nih.gov). For each chemical K nearest
neighbors are selected which serve as the local training dataset.
2. Selection of the most relevant classifier: Once the training dataset is established two types
of classifier selection techniques are used to select the most relevant classifier as described
below:
• Dynamic Classifier Selection (DCS): The final classification is based the predictive
accuracy of each in vitro assay is determined for each local training dataset. The in
vitro assay with the highest accuracy is selected as the most efficient classifier.
• Adaptive Classifier Selection (ACS): The final classification is based on how
accurately a class is predicted by the classifiers. Positive predictive value (PPV) and
negative predictive value (NPV) of each in vitro assay are determined for each local
training dataset. For each classifier the final selection is based on the higher value of
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PPV (positive) or NPV (negative). Finally, an average consensus decision based on
these predictions is used to make a final classification.
3. Classification of the test chemical: Each test chemical is classified based on prediction
made by the classifier identified in step 2 for the closest neighbor training data set.
The novelty of the proposed algorithm lies in the unique utilization of structural similarity
information for the construction of personalized training datasets and selection of the most relevant
classifier for each dataset. Similarity based training datasets are especially relevant in
characterization of the applicability domain of the model, which can be adjusted depending upon
the number of nearest neighbors selected. Moreover, since the prediction is based on a training
dataset of structurally similar chemicals, both the classifier selection and its outcome are
transparent.

5.4.2

Case Study: Using Chemical Similarity and In vitro Genotoxicity Data to
Develop a Hybrid QSAR-QBAR Model for In vivo Carcinogenicity Prediction

In vitro genotoxicity assays (e.g., Ames test) are widely used as an alternative to in vivo
animal testing methods for predicting the carcinogenic potential of chemicals used in consumer
products. However, genotoxicity assays are generally reported to show low concordance with high
rates of false negatives. False negatives or low sensitivity is especially undesirable under the
REACH regulations for regulatory acceptance of alternative methods for risk assessment.
Chapter 4 discussed an ensemble approach to address the issue of low sensitivity of
genotoxicity assays. In this chapter, the applicability of classifier selection algorithm is explored
for the integration of the concept of chemical structural similarity (borrowed from QSAR
modeling) with chemical response data from genotoxicity assays (biological data) in the selection
of the most reliable assay for each test chemical.

• Dataset
In vitro genotoxicity assay dataset described in Chapter 4, Section 4.3.2.1 is used in this
analysis. The dataset consists of chemical response data across 9 high-throughput in vitro
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genotoxicity assays (Ames, micronucleus, H2AXISV, Vitotox, Radarscreen, RAD51,
Cystatin, p53, Nrf2 [125, 126, 127]). The corresponding in vivo rodent carcinogenicity
information was obtained from publicly available carcinogenic potency database
(CPDB) [78] and chemical carcinogenesis research information system (CCRIS [79]). The
dataset consists of a total of 56 chemicals with the ratio of carcinogens to non-carcinogens of
31:25.
• Results
Table 5.3 shows the performance of genotoxicity assays in predicting carcinogenicity for the
ECVAM dataset. Classifier selection technique is used to determine the prediction for each
chemical based on leave one out cross validation. Table 5.4 shows the performance of the
model. The hybrid model boosts the sensitivity of predictions at the expense of specificity.
Variation in the number of closest neighbors can be made to select a desirable trade-off
between sensitivity and specificity as shown in the receiver operating curve (ROC) in
Figure 5.3.

Accuracy
(%)

Sensitivity
(%)

Specificity
(%)

Ames

67.86

45.16

96.00

MN

64.29

41.94

92.00

H2AXISV

69.94

51.61

92.00

Vitotox

64.29

41.94

92.00

Radarscreen

62.50

45.16

84.00

RAD51

60.71

35.48

92.00

Cystatin A

66.07

41.94

96.00

P53

66.07

48.39

88.00

Nrf2

62.50

54.84

72.00

In vitro Assay

Table 5.3: Performance metrics of genotoxicity assays. The highest value for each metric is highlighted in red.
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Model

Accuracy
(%)

Sensitivity
(%)

Specificity
(%)

Training Data Size = 5
DCS

57.14

67.74

44.00

ACS

50.00

54.84

44.00

Training Data Size = 10
DCS

55.36

54.84

56.00

ACS

46.43

67.74

20.00

Training Data Size = 15
DCS

48.21

32.26

68.00

ACS

57.14

70.97

40.00

Table 5.4: Performance metrics for classifier selection model. The highest value for each metric is
highlighted in red.

Figure 5.3: Receiver Operating Characteristic plot comparing the performance of the ACS and DCS
methods with varying number of nearest neighbors. The black line depicts a random classifier.
• Discussion
As discussed in Chapter 4, it is seen that the well accepted in vitro genotoxicity assays are
not very accurate predictors of in vivo carcinogenicity. In general, the sensitivity of
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genotoxicity assays is very low (< 50%) for carcinogenicity prediction. The performance of
the classifier selection technique does not improve the predictive ability to a great extent.
The success of the method depends on how well a test chemical is represented in the closest
neighbor training dataset i.e., closeness and the number of nearest neighbors.
The diversity of the chemical dataset used in this example is shown in Figure 5.4. The
heatmap shows that the chemicals in the EVCAM dataset are very dissimilar in nature where
most chemical pairs have a low Tanimoto score (< 0.5) and very few chemical pairs have a
high Tanimoto score (> 0.8). The method, therefore, needs to be validated using a chemical
dataset with more structurally similar compounds. Other measures of chemical similarity
can also be explored to determine the best structural analogs.

Figure 5.4: HeatMap representation of chemical diversity of the ECVAM dataset measured in terms
of Tanimoto distance. The annotations in each cell correspond to the distance between the two
chemicals (numbers). The colorbar on the right shows mapping of the distance (range: 0-1) to a
gray colorscale.
Nonetheless, the example demonstrates how the classifier selection method can be used to
develop type 2 hybrid QSAR-QBAR models for carcinogenicity prediction. The method can
also be used to predict any toxic endpoint with suitable selection of relevant in vitro assays.
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5.5

Conclusion
Development of novel hybrid QSAR-QBAR models is the next step in the advancement of

the field of predictive toxicology. This chapter introduced two novel algorithms for development of
hybrid models and discussed how they can improve the performance of existing methods. The case
studies demonstrate the proof-of-concept and the advantages of the proposed strategies over
existing QSAR and QBAR methods. These methods are expected to produce robust models
because they incorporate both structural similarity and biological similarity for predictive
toxicology.
The databases with the results of high-throughput in vitro screening of environmental
chemicals continue to grow. Most of this data is publically accessible and provides opportunities
for novel applications. With availability of more chemicals related to more and more toxic
endpoints, such data can be used for further evaluation of the methods developed in this chapter.
Synergistic use of relevant biological interactions and physicochemical/structural similarity better
represents the underlying complex mechanisms by which chemicals exert their toxic effects. Use
of in vitro data along with structural similarity in computational toxicology provides important
clues for identifying biomarkers and helps in refining the mechanistic understanding of the
mechanisms of toxicity (e.g.oxidative stress). These indications can support the design and
development of more focused short-term in vitro assays for specific toxic endpoints. This can,
further, improve the reliability and transparency of predictions in accordance with the legislative
guidelines for development of computational toxicology models. Thus, integration of QSAR and
QBAR modeling techniques for development of hybrid models has the potential of producing
powerful tools for toxicity prediction.

78

CHAPTER 6
CONCLUSION

”Hope is not the conviction that something will turn out well but the certainty that something
makes sense, regardless of how it turns out” - Vàclav Havel”

Computational or in silico toxicology has witnessed a significant influx of new methods in
the past few decades. Most of these technologies are driven by legislative regulations enforced by
the European Union for the risk assessment of xenobiotics used in consumer products for
protection of human and environmental health. Regulatory guidelines for development of in silico
models is driven partly by ever increasing concerns regarding the effects of long-term exposure to
a wide range of xenobiotics and partly by the need to maintain the ecological balance and ethical
considerations in reduction of animal models for toxicity testing.
Traditional in silico methods, Quantitative Structure Activity Relationships (QSARs), are
presently limited in their ability to accurately and reliably predict toxicity associated with newly
tailored and untested chemicals. The limitations in structure-activity correlation based QSAR
models can be attributed to the general challenges in modeling a complex phenomenon (such as
toxicity) and corroborating the model predictions with a firm scientific rationale. In the past few
decades, computational toxicology has embraced a focus on the use of mechanism based data in
training in silico models. Mechanistic approaches offer new avenues for un-earthing new
mechanisms for addressing the gaps in QSAR methods. Such approaches improve the confidence
in prediction since they are not just based on correlation but on the mechanistic knowledge of how
xenobiotics exert their toxic effects. Mechanism based approaches also align with the legislative
guidelines enforced by various regulatory organizations which ensure that in silico models are
reliable before they can be used for regulatory risk assessment. Toxicology has, thus, evolved from
phenomenon based remediation methods to in silico predictive methods to mechanism based
methods.
This disseration addresses some of the limitations associated with the use of current in
silico QSAR tools and explores novel methods for the development of mechanism based
computational toxicology models with special emphasis on regulatory considerations. Chapter 3
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addresses the issue of variability in toxicity predictions for a chemical by different in silico QSAR
tools. A novel method is presented for combining predictions from multiple in silico QSAR tools
to develop an ensemble QSAR tool. The method allows for flexibility in choosing a balance
between false positive and false negative predictions and, hence, the overall predictive ability of
the ensemble QSAR tool. This feature provides an additional control to the regulators in grading a
chemical based on the severity of the toxic endpoint under study. Chapter 4 addresses the concerns
in the use of mechanistically relevant in vitro assays in development of in silico tools for toxicity
prediction. Two novel methods are presented to demonstrate how to derive mechanistically
relevant in vitro data for the development of Quantitative Biological Activity Relationship (QBAR)
models for in vivo carcinogenicity prediction. The case studies show lower rates of false negatives
which is desirable under regulatory legislation. The results demonstrate how QBAR models can
sufficiently predict carcinogenicity when QSAR model predictions may fail. Chapter 5 presents
two novel methods for the fusion of QSAR and QBAR idealogies for the development of in silico
tools for toxicity prediction. These methods explore the capabilities of synergistic use of structural
similarity and mechanistic approaches to develop more powerful predictive models. Two case
studies are presented which demonstrate the feasibility of the proposed methods and their
relevance within regulatory guidelines.
There is still a lot to explore within and beyond the scope of this dissertation. There still
exists a need for development of new methods that incorporate different facets of chemical nature
for the development of rapid and reliable methods for computational prediction of toxicity. While
no single in silco tool can be deemed as a marvel, each one of them continues to contribute to the
overall development of the field of computational toxicology.
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APPENDIX A
DATASETS - CHAPTER 3

A.1

Dataset 1: Air Toxins
Table A.1: List of Chemicals for Dataset 1 (Air Toxins) in Chapter 3
No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

CASRN
2278-53-7
7287-82-3
630-20-6
71-55-6
79-00-5
75-34-3
75-35-4
156-59-2
87-61-6
96-18-4
95-94-3
120-82-1
95-63-6
930-87-0
84-78-6
96-12-8
106-93-4
95-50-1
107-06-2
78-87-5
122-66-7
106-88-7
2235-12-3
108-67-8
99-35-4
106-99-0
542-92-7
541-73-1
542-75-6
99-65-0
646-06-0
106-46-7
123-91-1
575-43-9
822-06-0

Chemical Name
[R-(E)]-5-isopropyl-8-methylnona-6,8,-dien-2-one
1-(2-methylphenyl)ethanol
1,1,1,2-tetrachloroethane
1,1,1-Trichloroethane
1,1,2-trichloroethane
1,1-dichloroethane
1,1,-Dichloroethylene (1,1-DCE)
1,2 (trans)-dichloroethylene
1,2,3-trichlorobenzene
1,2,3-Trichloropropane
1,2,4,5-tetrachlorobenzene
1,2,4-trichlorobenzene
1,2,4-trimethylbenzene
1,2,5-trimethylpyrrole
1,2-benzenedicarboxylic acid, butyl octy
1,2-dibromo-3-chloropropane
1,2-Dibromoethane
1,2-dichlorobenzene
1,2-dichloroethane
1,2-Dichloropropane
1,2-diphenylhydrazine
1,2-Epoxybutane (EBU)
1,3,5 hexatriene
1,3,5-trimethylbenzene
1,3,5-trinitrobenzene
1,3-Butadiene
1,3-cyclopentadiene
1,3-dichlorobenzene
1,3-Dichloropropene
1,3-dinitrobenzene
1,3-dioxalane
1,4-Dichlorobenzene
1,4-dioxane
1,6-dimethylnaphthalenea
1,6-Hexamethylene disocyanate
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No.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76

CASRN
75-68-3
622-96-8
621-32-9
874-41-9
620-14-4
622-96-8
592-41-6
3034-50-2
99-87-6
2886-59-1
767-59-9
99-85-4
3333-13-9
90-12-0
110-66-7
103-65-1
2409-55-4
2219-82-1
4901-51-3
58-90-2
28790-86-5
431-03-8
83-33-0
526-75-0
118-96-7
96-76-4
120-83-2
13494-06-9
565-80-0
105-67-9
51-28-5
26471-62-5
5875-45-6
120-52-5
3891-98-3
112-35-6
78-92-2
78-93-3
532-27-4
91-58-7
95-57-8

Chemical Name
1-Chloro-1,1-difluoroethane
1-ethenyl-4-methyl-benzene
1-ethoxy-3-methyl-benzene
1-ethyl-2,4-dimethyl-benzene
1-ethyl-3-methyl-benzene
1-ethyl-4-methylbenzene
1-hexene
1H-imidazole-4-carbaldehyde
1-isopropyl-4-methylbenzene
1-methoxy-1,4-cyclohexadiene
1-methyl-1H-indene
1-methyl-4-(1-methylethyl)1,4- cyclohexadiene
1-methyl-4-(2-propenyl)-benzene
1-methylnaphthalene
1-pentanethiol
1-propylbenzene
2-(1,1-dimethylethyl)-4-methyl-phenol
2-(1,1-dimethylethyl)-6-methyl-phenol
2,3,4,5-tetrachlorophenol
2,3,4,6-tetrachlorophenol
2,3,4-trimethyl-2-cyclopenten-1-one
2,3-butanedione
2,3-dihydro-1H-inden-1-one
2,3-dimethyl-phenol
2,4,6-trinitrotoluene
2,4-bis(1,1-dimethylethyl)-phenol
2,4-dichlorophenol
2,4-dimethyl-1,3-cyclopentanedione
2,4-dimethyl-3-pentanone
2,4-dimethylphenol
2,4-dinitrophenol
2,4/2,6-Toluene diisocyanate mixture (TDI)
2,5-bis(1,1-dimethylethyl)-phenol
2,5-cyclohexadiene-1,4-dione, bis(O-benzoyloxime)
2,6,10-trimethyldodecane
2-[2-(2-methoxyethoxy)ethoxy]-ethanol
2-butanol
2-butanone
2-Chloroacetophenone
2-chloronaphthalenea
2-chlorophenol
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No.
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117

CASRN
693-54-9
769-25-5
110-80-5
1758-88-9
104-76-7
1551-06-0
123-05-7
591-78-6
90-02-8
1195-09-1
109-86-4
636-41-9
75-66-1
565-69-5
78-78-4
91-57-6
95-48-7
75-66-1
78-84-2
554-14-3
7045-71-8
88-74-4
79-46-9
821-55-6
111-13-7
2809-67-8
107-87-9
21915-53-7
75-33-2
873-94-9
119-90-4
27129-87-9
108-68-9
26472-00-4
21835-01-8
767-60-2
563-80-4
590-86-3
96-14-0
108-39-4
99-09-2

Chemical Name
2-decanone
2-ethenyl-1,3,5-trimethyl-benzene
2-Ethoxyethanol
2-ethyl-1,4-dimethylbenzene
2-ethyl-1-hexanol
2-ethyl-1H-pyrrole
2-ethylhexanal
2-Hexanone
2-hydroxybenzaldehyde
2-methoxy-5-methylphenol
2-Methoxyethanol
2-methyl-1H-pyrrole
2-methyl-2-propanethiol
2-methyl-3-pentanone
2-methylbutane
2-methylnaphthalenea
2-methylphenol
2-methyl-propane-2-thiol
2-methylpropanal
2-methylthiophene
2-methylundecane
2-nitroaniline
2-Nitropropane
2-nonanone
2-octanone
2-octyne
2-pentanone
2-phenyl-oxiranemethanol
2-propanethiol
3,3,5-trimethylcyclohexanone
3,3-dimethoxybenzidine
3,5-dimethyl-benzenemethanol
3,5-dimethyl-phenol
”3a,4,7,7a-tetrahydrodimethyl-4,7-methano-1H-inde”
3-ethyl-2-hydroxy-2-cyclopenten-1-one
3-methyl-1H-indene
3-methyl-2-butanone
3-methylbutanal
3-methylpentane
3-methylphenol
3-nitroaniline
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No.
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158

CASRN
24851-98-7
96-22-0
101-55-3
59-50-7
7005-72-3
2896-60-8
4748-78-1
121-33-5
150-76-5
108-10-1
141-79-7
104-87-0
589-18-4
106-44-5
100-01-6
3775-01-7
15356-70-4
17312-76-4
514-10-3
75-07-0
75-05-8
98-86-2
107-02-8
79-06-1
79-10-7
107-13-1
107-05-1
319-84-6
62-53-3
120-12-7
12674-11-2
100-52-7
71-43-2
60-12-8
56-55-3
50-32-8
191-24-2
65-85-0
100-47-0
100-51-6
100-44-7

Chemical Name
3-oxo-2-pentyl-cyclopentaneacetic acid
3-pentanone
4-bromophenyl-phenylether
4-chloro-3-methylphenol
4-chlorophenyl-phenylether
4-ethyl-1,3-benzenediol
4-ethylbenzaldehyde
4-hydroxy-3-methoxybenzaldehyde
4-methoxyphenol
4-methyl-2-pentanone
4-methyl-3-penten-2-one
4-methylbenzaldehyde
4-methyl-benzenemethanol
4-methylphenol(p-cresol)
4-nitroaniline
5-benzylidenehydantoin
5-methyl-2-(1-methylethyl)-cyclohexanol
6,6-dimethylundecane
abietic acid
Acetaldehyde
Acetonitrile
acetophenone
Acrolein
Acrylamide
Acrylic acid
Acrylonitrile
Allyl chloride
alpha-hexachlorocyclohexane
Aniline
anthracenea
aroclor 1016
benzaldehyde
Benzene
benzeneethanol
benzo(a)anthracenea
benzo(a)pyrene
benzo(ghi)perylenea
benzoic acid
benzonitrile
benzyl alcohol
benzyl chloride
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No.
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199

CASRN
319-85-7
92-52-4
111-44-4
108-60-1
464-41-5
108-86-1
75-27-4
75-25-2
74-83-9
123-72-8
106-97-8
107-92-6
128-37-0
123-72-8
56-23-5
108-90-7
75-45-6
75-00-3
218-01-9
156-59-2
123-73-9
98-82-8
592-57-4
110-82-7
108-94-1
108-91-8
542-92-7
124-18-5
53-70-3
124-48-1
75-09-2
75-71-8
62-73-7
110-81-6
84-66-2
352-93-2
108-83-8
624-92-0
131-11-3
75-18-3
3658-80-8

Chemical Name
beta-hexachlorocyclohexane
biphenyl
bis(2-chlorethyl)ether
bis-1,2-chloroisopropyl ether
bornyl chloride
Bromobenzene
bromodichloromethane
bromoform
Bromomethane
butanal
butane
butanoic acid
butylated hydroxytoluene
butyraldehyde
Carbon tetrachloride
chlorobenzene
Chlorodifluoromethane
chloroethane
chrysene a
cis-1,2-dichloroethylene
crotonaldehyde
Cumene
cyclohexa-1,3-diene
Cyclohexane
cyclohexanone
cyclohexylamine
cyclopentadiene
decane
dibenzo(ah)anthracene a
dibromochloromethane
Dichloromethane
dichlorodifluoromethane
Dichlorvos
diethyl disulfide
diethyl phthalate
diethyl sulfide
diisobutylketone
dimethyl disulfide
dimethyl phthalate
dimethyl sulfide
dimethyl trisulfide
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No.
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240

CASRN
127-19-5
2432-89-5
117-84-0
112-40-3
112-95-8
506-30-9
106-89-8
75-08-1
64-17-5
75-00-3
111-76-2
97-63-2
62-50-0
624-89-5
100-41-4
106-93-4
75-21-8
64-18-6
629-78-7
142-82-5
111-14-8
87-68-3
118-74-1
77-47-4
67-72-1
70-30-4
544-76-3
66-25-1
110-54-3
95-13-6
79-77-6
75-28-5
78-59-1
67-63-0
98-82-8
50-21-5
97-67-6
78-85-3
126-98-7
74-93-1
79-20-9

Chemical Name
dimethylacetamide
di-n-decyl sebacate
di-n-octylphthalate
dodecane
eicosane
eicosanoic acid
Epichlorohydrin
ethanethiol
ethanol
Ethyl Chloride
Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)
ethyl methacrylate
ethyl methanesulfonate
ethyl methyl sulfide
Ethylbenzene
ethylene dibromide
ethylene oxide
formic acid
heptadecane
heptane
heptanoic acid
hexachloro-1,3-butadiene
hexachlorobenzene
Hexachlorocyclopentadiene (HCCPD)
Hexachloroethane
hexachlorophene
hexadecane
hexaldehyde
n-Hexane
indene
ionone
iso-butane
isophorone
iso-propanol
isopropylbenzene
lactic acid
malic acid
methacrolein
methacrylonitrile
methanethiol
methyl acetate
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No.
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281

CASRN
74-83-9
74-87-3
78-93-3
108-10-1
80-62-6
298-00-0
1634-04-4
108-87-2
96-37-7
74-95-3
75-09-2
101-68-8
78-98-8
91-20-3
68-12-2
629-97-0
463-82-1
629-94-7
57-10-3
98-95-3
924-16-3
86-30-6
621-64-7
111-84-2
103-65-1
14167-59-0
638-68-6
57-11-4
111-65-9
95-53-4
144-62-7
106-47-8
608-93-5
82-68-8
87-86-5
109-66-0
4292-92-6
85-01-8
108-95-2
60-12-8
75-44-5

Chemical Name
methyl bromide
Methyl chloride
Methyl ethyl ketone (MEK)
Methyl isobutyl ketone (MIBK)
Methyl methacrylate
methyl parathion
Methyl tert-butyl ether (MTBE)
methylcyclohexane
methylcyclopentane
methylene bromide
methylene chloride
Methylene Diphenyl Diisocyanate and polymeric MDI
methylglyoxal
Napthalene
N,N-Dimethylformamide
n-docosane
neo-pentane
n-heneicosane
n-hexadecanoic acid
Nitrobenzene
n-nitroso-di-n-butylamine
n-nitrosodiphenylamine
n-nitrosodipropylamine
nonane
n-propylbenzene
n-tetratriacontane
n-triacontane
octadecanoic acid
octane
o-toluidine
oxalic acid
p-chloroaniline
pentachlorobenzene
pentachloronitrobenzene
pentachlorophenol
pentane
pentylcyclohexane
phenanthrenea
phenol
phenylethanol
Phosgene
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No.
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315

A.2

CASRN
85-44-9
123-38-6
74-98-6
75-33-2
115-07-1
123-38-6
107-98-2
75-56-9
129-00-0
110-86-1
3232-37-9
100-42-5
127-18-4
629-59-4
109-99-9
7098-22-8
108-88-3
79-01-6
75-69-4
67-66-3
629-50-5
121-44-8
75-50-3
540-84-1
791-28-6
1120-21-4
110-62-3
121-33-5
108-05-4
593-60-2
75-01-4
95-47-6
106-42-3
544-25-2

Chemical Name
phthalic anhydride
propanal
propane
propane-2-thiol
propene
Propionaldehyde
Propylene glycol monomethyl ether (PGME)
Propylene oxide
pyrenea
pyridine
salicylidene benzhydrazide
Styrene
Tetrachloroethylene
tetradecane
Tetrahydrofuran
tetratetracontane
Toluene
Trichloroethylene
trichlorofluoromethane
trichloromethane
tridecane
Triethylamine
trimethylamine
2,2,4-Trimethylpentane
triphenylphosphine oxide
undecane
valeraldehyde
vanillin
Vinyl acetate
Vinyl bromide
Vinyl chloride
o-Xylene
p-Xylene
1,3,5-cycloheptatriene

Dataset 2: Medical Device Leachables
Data cannot be shared.
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A.3

Dataset 3: Subset of Carcinogenic Potency Database
Table A.2: List of Chemicals for Dataset 3 (CPDB) in Chapter 3
No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

CASRN
62-73-7
126-72-7
597-25-1
52-68-6
531-18-0
513-37-1
593-60-2
75-02-5
75-01-4
305-03-3
50-18-0
148-82-3
3546-10-9
51-75-2
3068-88-0
1955-45-9
1120-71-4
57-57-8
106-92-3
101-90-6
77-83-8
75-21-8
106-87-6
556-52-5
57-39-6
122-60-1
75-56-9
96-09-3
52-24-4
298-18-0
106-88-7
100-44-7
3296-90-0
108-60-1
75-27-4
109-69-3
75-88-7
532-27-4

Chemical Name
Dichlorvos
Tris(2,3-dibromopropyl) phosphate
Dimethyl morpholinophosphoramidate
Trichlorfon
Hexamethylmelamine
Dimethylvinyl chloride (DMVC)
Vinyl bromide
Ethene, fluoroEthene, chloroChlorambucil
Cyclophosphamide
Melphalan
Phenesterin
Nitrogen mustard
beta-Butyrolactone
Pivalolactone
Propane sultone
Propiolactone
Allyl glycidyl ether
Diglycidyl resorcinol ether, technical grade
Ethyl-3-methyl-3-phenylglycidate
Ethylene oxide
4-Vinyl-1-cyclohexene diepoxide
Glycidol
Metepa
Phenyl glycidyl ether
1,2-Propylene oxide
Styrene oxide
Tris(aziridinyl)-phosphine sulfide (thio-tepa)
1,2,3,4-Diepoxybutane DL
1,2-Epoxybutane
Benzyl chloride
2,2-Bis(bromomethyl)-1,3-propanediol, technical grade
Bis(2-chloro-1-methylethyl)ether, technical grade
Bromodichloromethane
n-Butyl chloride
2-Chloro-1,1,1-trifluoroethane
2-Chloroacetophenone (CN)

99

No.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79

CASRN
124-48-1
107-30-2
96-12-8
106-93-4
107-06-2
78-87-5
72-56-0
306-83-2
144-48-9
75-47-8
3778-73-2
576-68-1
74-83-9
79-11-8
79-34-5
15318-45-3
75-25-2
79-00-5
96-18-4
542-88-1
74-96-4
75-45-6
75-00-3
593-70-4
75-34-3
96-24-2
75-09-2
10318-26-0
79-43-6
542-56-3
79-06-1
14484-47-0
50-02-2
50-23-7
78-59-1
123-33-1
50-24-8
37076-68-9
76-25-5
66-22-8
34661-75-1

Chemical Name
Chlorodibromomethane
Chloromethyl methyl ether
1,2-Dibromo-3-chloropropane
1,2-Dibromoethane
1,2-Dichloroethane
1,2-Dichloropropane (propylene dichloride)
Di(p-ethylphenyl)dichloroethane
Ethane, 2,2-dichloro-1,1,1-trifluoroIodoacetamide
Iodoform
Isophosphamide
Mannitol nitrogen mustard
Methyl bromide
Monochloroacetic acid
1,1,2,2-Tetrachloroethane
Thiamphenicol
Tribromomethane
1,1,2-Trichloroethane
1,2,3-Trichloropropane
Bis(chloromethyl) ether
Bromoethane (ethyl bromide)
Methane, chlorodifluoroChloroethane
Chlorofluoromethane
1,1-Dichloroethane
3-Chloro-1,2-propanediol
Methylene chloride
Dibromodulcitol
Dichloroacetic acid
Isobutyl nitrite
Acrylamide
Deflazacort
Dexamethazone
Hydrocortisone
Isophorone
Maleic hydrazide
Prednisolone
Tegafur
Triamcinolone acetonide
Uracil
Urapidil
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No.
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120

CASRN
518-75-2
51-21-8
75-07-0
100-52-7
98-01-1
129-43-1
129-15-7
117-10-2
81-54-9
57-14-7
34176-52-8
122-66-7
54-85-3
6294-89-9
671-16-9
32852-21-4
2411-74-7
1156-19-0
25843-45-2
622-78-6
2257-09-2
10473-70-8
598-55-0
51-79-6
1212-29-9
96-45-7
13752-51-7
97-77-8
137-26-8
62-55-5
62-56-6
2489-77-2
105-55-5
50-32-8
56-49-5
128-66-5
244-63-3
115-28-6
143-50-0
39801-14-4
2385-85-5

Chemical Name
Citrinin
5-Fluorouracil
Acetaldehyde
Benzaldehyde
Furfural
1-Hydroxyanthraquinone
2-Methyl-1-nitroanthraquinone
Danthron
Purpurin
Dimethyl hydrazine (DMH)
2-Hydrazino-4-phenylthiazole
Hydrazobenzene
Isoniazid
Methyl carbazate
Procarbazine
Formic acid 2-(4-methyl-2-thiazolyl)hydrazide
2-Furaldehyde semicarbazone
Tolazamide
Azoxymethane
Benzyl isothiocyanate
Phenethyl isothiocyanate
1-(4-Chlorophenyl)-1-phenyl-2-propynyl carbamate
Methyl carbamate
Urethane
N,N’-Dicyclohexylthiourea
Ethylene thiourea (ETU)
Morpholine, 4-[(4-morpholinylthio)thioxomethyl]Tetraethylthiuram disulfide
Tetramethylthiouram disulfide
Thioacetamide
Thiourea
Trimethylthiourea
N,N’-Diethylthiourea
Benzo(a)pyrene
3-Methylcholanthrene
C.I Vat yellow 4
Norharman
Chlorendic acid
Chlordecone (kepone)
Mirex, photoMirex
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No.
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161

CASRN
760-56-5
10589-74-9
16338-97-9
56654-52-5
3276-41-3
3851-16-9
55557-00-1
38434-77-4
14026-03-0
16813-36-8
55090-44-3
684-93-5
55556-92-8
51542-33-7
53609-64-6
60599-38-4
924-16-3
1116-54-7
55-18-5
62-75-9
86-30-6
621-64-7
17608-59-2
10595-95-6
614-95-9
30310-80-6
26921-68-6
614-00-6
59-89-2
4515-18-8
930-55-2
816-57-9
18883-66-4
40548-68-3
3817-11-6
869-01-2
13256-06-9
13743-07-2
760-60-1
13256-11-6
1133-64-8

Chemical Name
1-Allyl-1-nitrosourea
1-Amyl-1-nitrosourea
Diallylnitrosamine
1,3-Dibutyl-1-nitrosourea
3,6-Dihydro-2-nitroso-2H-1,2-oxazine
N,N’-Dimethyl-N,N’-dinitrosophthalamide
Dinitrosohomopiperazine
Ethylnitrosocyanamide
R(-)-2-Methyl-N-nitrosopiperidine
1-Nitroso-5,6-dihydrouracil
N-Nitroso-N-methyl-N-dodecylamine
N-Nitroso-N-methylurea
Nitroso-1,2,3,6-tetrahydropyridine
N-Nitrosobenzthiazuron
N-Nitrosobis(2-hydroxypropyl)amine
N-Nitrosobis(2-oxopropyl)amine
Nitrosodibutylamine
N-Nitrosodiethanolamine
N-Nitrosodiethylamine
N-Nitrosodimethylamine
N-Nitrosodiphenylamine
N-Nitrosodipropylamine
N-Nitrosoephedrine
Nitrosoethylmethylamine
Nitrosoethylurethane
Nitrosohydroxyproline
N-Nitrosomethyl-(2-hydroxyethyl) amine
Nitrosomethylaniline
N-Nitrosomorpholine
Nitrosopipecolic acid
N-Nitrosopyrrolidine
N-Propyl-N-nitrosourea
Streptozotocin
Tetrahydro-2-nitroso-2H-1,2-oxazine
n-Butyl-N-(4-hydroxybutyl)nitrosamine
N-n-Butyl-N-nitrosourea
Dipentylnitrosamine
1-(2-Hydroxyethyl)-1-nitrosourea
N-Nitroso-N-isobutylurea
Nitroso-N-methyl-N-(2-phenyl)ethylamine
Nitrosoanabasine
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No.
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202

CASRN
625-89-8
42579-28-2
5632-47-3
100-75-4
7519-36-0
26541-51-5
7227-91-0
4164-28-7
598-57-2
108-05-4
611-23-4
3688-53-7
88-73-3
100-00-5
551-92-8
606-20-2
298-00-0
139-94-6
92-55-7
91-23-6
98-95-3
1836-75-5
86-57-7
607-35-2
56-38-2
99-35-4
97-00-7
443-48-1
62-23-7
613-50-3
91-76-9
108-78-1
396-01-0
59-05-2
303-34-4
22571-95-5
315-22-0
97-53-0
52214-84-3
77-92-9
104-76-7

Chemical Name
N-Nitrosobis(2,2,2-trifluoroethyl) amine
1-Nitrosohydantoin
N-Nitrosopiperazine
N-Nitrosopiperidine
Nitrosoproline
N-Nitrosothiomorpholine
1-Phenyl-3,3-dimethyltriazene
Dimethylnitramine
Methylnitramine
Vinyl acetate
o-Nitrosotoluene
AF-2
2-Chloronitrobenzene
4-Chloronitrobenzene
1,2-Dimethyl-5-nitroimidazole
2,6-Dinitrotoluene
Methyl parathion
Nithiazide
5-Nitro-2-furanmethanediol diacetate
o-Nitroanisole
Nitrobenzene
Nitrofen
1-Nitronaphthalene
8-Nitroquinoline
Parathion
1,3,5-Trinitrobenzene
Dinitrochlorobenzene
Metronidazole
p-Nitrobenzoic acid
6-Nitroquinoline
1,3,5-Triazine-2,4-diamine, 6-phenylMelamine
Triamterene
Methotrexate
Lasiocarpine
Symphytine
Monocrotaline
Eugenol
Ciprofibrate
1,2,3-Propanetricarboxylic acid, 2-hydroxy2-Ethylhexanol
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No.
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243

CASRN
25812-30-0
78-42-2
75330-75-5
131-17-9
85-68-7
87-68-3
127-18-4
116-14-3
79-01-6
1825-21-4
476-66-4
90-43-7
51481-61-9
86315-52-8
50-44-2
58-55-9
148-79-8
73590-58-6
58-93-5
54-31-9
94-58-6
120-62-7
533-31-3
56-23-5
67-72-1
72-43-5
76-03-9
51-52-5
30516-87-1
141-90-2
477-30-5
123-73-9
2475-45-8
81-49-2
117-79-3
82-28-0
79-19-6
142-46-1
13010-08-7
59-87-0
2302-84-3

Chemical Name
Gemfibrozil
Tris(2-ethylhexyl)phosphate
Lovastatin
Diallyl phthalate
Butyl benzyl phthalate
Hexachloro-1,3-butadiene
Tetrachloroethylene
Tetrafluoroethylene
Trichloroethylene
Pentachloroanisole
Ellagic acid
o-Phenylphenol
Cimetidine
Isomazole
6-Mercaptopurine
Theophylline
Thiabendazole
Omeprazole
Hydrochlorothiazide
Furosemide
Dihydrosafrole
Piperonyl sulfoxide
Sesamol
Carbon tetrachloride
Hexachloroethane
Methoxychlor
Trichloroacetic acid
6-Propyl-2-thiouracil
3’-Azido-3’-deoxythymidine (AIDS)
Thiouracil
Colcemid
Crotonaldehyde
C.I. Disperse blue 1
1-Amino-2,4-dibromoanthraquinone
2-Aminoanthraquinone
1-Amino-2-methylanthraquinone
Thiosemicarbazide
2,5-Dithiobiurea
N-Butyl-N’-nitro-N-nitrosoguanidine
Nitrofurazone
1-Formyl-3-thiosemicarbazide
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No.
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284

CASRN
3570-75-0
555-84-0
91-93-0
103-85-5
5522-43-0
53-95-2
3096-50-2
607-57-8
363-17-7
28314-03-6
53-96-3
28322-02-3
67730-10-3
76180-96-6
943-41-9
5461-85-8
13010-10-1
99-80-9
70-25-7
13010-07-6
34627-78-6
94-52-0
121-88-0
5307-14-2
2425-85-6
712-68-5
99-56-9
99-55-8
99-57-0
119-34-6
1777-84-0
6471-49-4
121-66-4
446-86-6
1582-09-8
531-82-8
619-17-0
33229-34-4
15721-02-5
97-56-3
58-14-0

Chemical Name
Formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide
1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone
3,3’-Dimethoxybenzidine-4,4’-diisocyanate
1-Phenyl-2-thiourea
1-Nitropyrene
N-Hydroxy-2-acetylaminofluorene
N-(9-Oxo-2-fluorenyl)acetamide
2-Nitrofluorene
N-(2-Fluorenyl)-2,2,2-trifluoroacetamide
1-Acetylaminofluorene
2-Acetylaminofluorene
4-Acetylaminofluorene
Glu-P-2
IQ
N-Nitroso-N-methyl-4-nitroaniline
N-Isobutyl-N’-nitro-N-nitrosoguanidine
N-Pentyl-N’-nitro-N-nitrosoguanidine
N-Methyl-N,4-dinitrosoaniline
1-Methyl-3-nitro-1-nitroso-guanidine
N-Propyl-N’-nitro-N-nitrosoguanidine
1’-Acetoxysafrole
6-Nitrobenzimidazole
2-Amino-5-nitrophenol
2-Nitro-p-phenylenediamine
C.I. Pigment red 3
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole
4-Nitro-o-phenylenediamine
5-Nitro-o-toluidine
2-Amino-4-nitrophenol
4-Amino-2-nitrophenol
3-Nitro-p-acetophenetide
C.I. Pigment red 23
2-Amino-5-nitrothiazole
Azathioprine
Trifluralin, technical grade
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide
4-Nitroanthranilic acid
HC blue 2
2,2’,5,5’-Tetrachlorobenzidine
o-Aminoazotoluene
Pyrimethamine
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No.
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325

CASRN
80-08-0
95-80-7
91-94-1
106-50-3
133-90-4
101-14-4
2243-62-1
101-80-4
5131-60-2
95-74-9
95-79-4
838-88-0
92-87-5
102-50-1
120-71-8
609-20-1
62-53-3
101-79-1
137-17-7
91-59-8
106-47-8
1912-24-9
60-11-7
55-80-1
101-61-1
2784-94-3
121-69-7
90-94-8
2832-40-8
398-32-3
4463-22-3
62-44-2
6673-35-4
77-46-3
18699-02-0
103-33-3
842-07-9
599-79-1
924-42-5
22131-79-9
101-05-3

Chemical Name
4,4’-Sulfonyldianiline (Dapsone)
2,4-Diaminotoluene (2,4-toluene diamine)
3,3’-Dichlorobenzidine
1,4-Benzenediamine
Chloramben
4,4’-Methylenebis(2-chloroaniline)
1,5-Naphthalenediamine
4,4’-Oxydianiline
4-Chloro-m-phenylenediamine
3-Chloro-p-toluidine
5-Chloro-o-toluidine
4,4’-Methylene-bis(2-methylaniline)
Benzidine
m-Cresidine
p-Cresidine
2,6-Dichloro-p-phenylenediamine
Aniline
4-Chloro-4’-aminodiphenylether
2,4,5-Trimethylaniline
2-Naphthylamine
p-Chloroaniline
Atrazine
4-Dimethylaminoazobenzene
3’-Methyl-4-dimethylaminoazobenzene
4,4’-Methylenebis(N,N-dimethyl)benzenamine
HC blue 1
N,N-Dimethylaniline
Michler’s ketone
C.I. Disperse yellow 3
N-4-(4’-Fluorobiphenyl)acetamide
3-Hydroxy-4-acetylaminobiphenyl
Phenacetin
Practolol
4,4’-Sulfonylbisacetanilide
4-Acetylaminophenylacetic acid
Azobenzene
C.I Solvent yellow 14
Salicylazosulfapyridine
N-Methylolacrylamide
Alclofenac
Anilazine
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No.
326
327
328
329
330
331
332
333
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367

CASRN
37087-94-8
2698-41-1
108-90-7
94-20-2
106-46-7
53-86-1
2227-13-6
72-55-9
115-32-2
94-59-7
95-06-7
103-23-1
133-07-3
23255-69-8
765-34-4
106-89-8
76-01-7
56980-93-9
101-21-3
135-88-6
74-31-7
622-51-5
5979-28-2
968-81-0
79-10-7
107-18-6
60-32-2
60142-96-3
57-43-2
50-81-7
22839-47-0
51-55-8
71-43-2
271-89-6
120-32-1
110-97-4
96-48-0
58-08-2
105-60-2
7235-40-7
50892-23-4

Chemical Name
2-Chloro-5-(3,5-dimethylpiperidinosulphonyl)benzoic acid
o-Chlorobenzalmalononitrile (CS)
Chlorobenzene
Chlorpropamide
1,4-Dichlorobenzene (p-dichlorobenzene)
Indomethacin
p-Chlorophenyl-2,4,5-trichlorophenyl sulfide
p,p’-Dichlorodiphenyl dichloroethylene
Dichlorodiphenyltrichloroethane (DDT)
Safrole
Sulfallate
Di(2-ethylhexyl)adipate
N-(Trichloromethylthio)phthalimide
Fusarenon-X
Glycidaldehyde
Epichlorhydrin
Pentachloroethane
Celiprolol
Isopropyl-N-(3-chlorophenyl) carbamate
N-Phenyl-2-naphthylamine
N,N’-Diphenyl-p-phenylenediamine
p-Tolylurea
C.I. pigment yellow 16
Acetohexamide
Acrylic acid
Allyl alcohol
6-Aminocaproic acid
1-(Aminomethyl)cyclohexaneacetic acid
Amobarbital
L-Ascorbic acid
Aspartame
Atropine
Benzene
Benzofuran
o-Benzyl-p-chlorophenol
Diisopropanolamine
Gamma-butyrolactone
Caffeine
Caprolactam
beta-Carotene
(4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio) acetic acid
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No.
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408

CASRN
22494-47-9
76-57-3
31698-14-3
1192-28-5
53-43-0
333-41-5
1717-00-6
2921-88-2
111-46-6
56-53-1
60-51-5
120-61-6
127-19-5
57-41-0
63-84-3
2629-59-6
100-41-4
41340-25-4
55-38-9
118-74-1
319-84-6
77-47-4
70-30-4
100-97-0
136-77-6
15687-27-1
5989-27-5
1634-78-2
89-78-1
67-98-1
149-30-4
493-78-7
150-76-5
1634-04-4
872-50-4
98-85-1
452-86-8
119-47-1
91-62-3
54-11-5
139-13-9

Chemical Name
Clobuzarit
Codeine
Cyclocytidine
Cyclopentanone oxime
Dehydroepiandrosterone
Diazinon
Ethane, 1,1-dichloro-1-fluoroChlorpyrifos (Dursban)
Diethylene glycol
Diethylstilbestrol
Dimethoate
Dimethyl terephthalate
N,N-Dimethylacetamide
5,5-Diphenylhydantoin (phenytoin)
dl-Dopa
S-Ethyl-l-cysteine
Ethylbenzene
Etodolac
Fenthion
hexachlorobenzene
alpha-1,2,3,4,5,6-Hexachlorocyclohexane
Hexachlorocyclopentadiene (HCCPD)
Hexachlorophene
Urotropine
4-Hexylresorcinol
Ibuprofen
D-Limonene
Malaoxon
dl-Menthol
MER-25
2-Mercaptobenzothiazole
Methaphenilene
Hydroquinone monomethyl ether
Methyl-t-butyl ether
N-Methyl-2-pyrrolidone
alpha-Methylbenzyl alcohol
p-Methylcatechol
Phenol, 2,2’-methylenebis[6-(1,1-dimethylethyl)-4-methyl6-Methylquinoline
Nicotine
Nitrilotriacetic acid (NTA)
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No.
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449

CASRN
600-24-8
75-52-5
64224-21-1
23135-22-0
149-29-1
108-95-2
77-09-8
92-13-7
110-85-0
110-89-4
57-66-9
121-79-9
115-07-1
57-55-6
99-50-3
98-96-4
108-46-3
127-47-9
79-81-2
81-07-2
108-30-5
107-35-7
732-26-3
2438-88-2
109-99-9
91-79-2
96-69-5
64-77-7
88-19-7
76-13-1
71-55-6
75-69-4
88-06-2
112-27-6
127-48-0
458-37-7
57-13-6
88-12-0
127-06-0
616-91-1
2835-39-4

Chemical Name
2-Nitrobutane
Nitromethane
Oltipraz
Oxamyl
Patulin
Phenol
Phenolphthalein
Pilocarpine
Piperazine
Piperidine
Probenecid
Propyl gallate
Propylene
1,2-Propylene glycol
Protocatechuic acid
Pyrazinamide
Resorcinol
Retinol acetate
All-trans-retinyl palmitate
Saccharin
Succinic anhydride
L-Taurine
Phenol, 2,4,6-tris(1,1-dimethylethyl)2,3,5,6-Tetrachloro-4-nitroanisole
Ethane, 1,1,1,2-tetrafluoroThenyldiamine
4,4-Thiobis(6-tert-butyl-m-cresol)
Tolbutamide
o-Toluenesulfonamide
1,1,2-Trichloro-1,2,2-trifluoroethane, technical grade
1,1,1-Trichloroethane, technical grade
Trichlorofluoromethane
2,4,6-Trichlorophenol
Triethylene glycol
Trimethadione
Turmeric ( 98% curcurmin)
Urea
2-Pyrrolidinone, 1-ethenylAcetoxime
N-acetylcysteine
Allyl isovalerate
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No.
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480

CASRN
2432-99-7
4180-23-8
65-85-0
331-39-5
853-23-6
95-50-1
94-75-7
685-91-6
62488-57-7
13265-60-6
13073-35-3
64-17-5
111-68-2
148-24-3
115-11-7
121-75-5
531-06-6
112-63-0
578-76-7
95-71-6
79-24-3
79-46-9
50-06-6
89-25-8
1918-02-1
105-11-3
23031-25-6
1972-08-3
538-23-8
95-63-6
75-38-7

Chemical Name
11-Aminoundecanoic acid
Benzene, 1-methoxy-4-(1E)-1-propenylBenzoic acid
3,4-Dihydroxycinnamic acid
Dehydroepiandrosterone acetate
1,2-Dichlorobenzene (o-dichlorobenzene)
2,4-Dichlorophenoxyacetic acid
Diethylacetamide
5,6-Dihydro-5-azacytidine
O,O-Dimethyl S-2(acetylamino)ethyl dithiophosphate, TG
Ethionine (DL-ethionine)
Ethanol
Heptylamine
8-Hydroxyquinoline
Isobutene
Malathion
Methafurylene
Methyl linoleate, native
7-Methylguanine
Methylhydroquinone
Nitroethane
2-Nitropropane
Phenobarbital
1-Phenyl-3-methyl-5-pyrazolone
Picloram, technical grade
p-Benzoquinone dioxime
Terbutaline
1-trans-delta-9-Tetrahydrocannabinol
Tricaprylin
Benzene, 1,2,4-trimethylVinylidene fluoride
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APPENDIX B
DATASETS - CHAPTER 4

B.1

No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Case Study 4.3.1: Identification of a Novel Biological Descriptor
Based on Xenobiotic Induced Cytochrome P450 Transcription
for Carcinogenicity Prediction
Dataset 1 (6hr Exposure)
Chemical Name
CASRN
Carboxin
5234-68-4
Chlorpyrifos oxon
5598-15-2
Cypermethrin
52315-07-8
Diazinon
333-41-5
Disulfoton
298-04-4
Fenitrothion
122-14-5
Fenthion
55-38-9
Indoxacarb
173584-44-6
Isazofos
42509-80-8
Lactofen
77501-63-4
Methoxychlor
72-43-5
Parathion
56-38-2
Parathion-methyl
298-00-0
Piperonyl butoxide
51-03-6
Propazine
139-40-2
Thiophanate-methyl 23564-05-8
Trifluralin
1582-09-8

No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Dataset 2 (24hr Exposure)
Chemical Name
CASRN
Acetochlor
34256-82-1
Azinphos-methyl
86-50-0
Bromacil
314-40-9
Carboxin
5234-68-4
Diazinon
333-41-5
Diuron
330-54-1
Fentin
76-87-9
Indoxacarb
173584-44-6
Iprodione
36734-19-7
Isazofos
42509-80-8
Lactofen
77501-63-4
Linuron
330-55-2
Methidathion
950-37-8
Parathion
56-38-2
Propazine
139-40-2
Trifluralin
1582-09-8

Table B.1: List of Chemicals for Case Study 4.3.1 in Chapter 4

B.2

Case Study 4.3.2: QBAR Model of In-vitro Genotoxicity Assays
for Carcinogenicity Prediction
No.
1
2
3
4
5
6

Chemical Name
CPA
ENU
MMS
BaP
DMBA
DMNA

CASRN
6055-19-2
759-73-9
66-27-3
50-32-8
57-97-6
62-75-9
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No.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Chemical Name
2-AAF
2,4 - DAT
2,Amino-3-methylimidazo
2-amino-1,6-dimethylimidazo
AFB1
Cadmium chloride
Cisplatin
p-Chloroaniline
Etoposide (ETO)
Hydroquinone
AZT
Sodium arsenite
Chloramphenicol
Ampicillin trihydrate
D-Mannitol
Phenforim HCl
n-Butyl chloride
2-Chloroethyl]trimethyl-ammonium chloride
Cyclohexanone
N,N-Dicyclohexyl thiourea
Trisdoium EDTA trihydrate
Erythromycin stearate
Flumetron
Phenanthrene
D-limonene
Di-[2-ethylhexyl]phtalate
Amitrole
tert-butyl alcohol
Diethanolamine
Melamine
Methyle carbamate
Progesterone
Pyridine
Tris[2-ethylhexyl]phosphate
Hexachloroethane
D,L-menthol
Pthalic anhydride
o-Anthranilic acid
Reorcinol
2-Ethyl-1,3-hexanediol

CASRN
53-96-3
95-80-7
76180-96-6
132898-04-5
1162-65-8
10108-64-2
15663-27-1
106-47-8
33419-42-0
123-31-9
30516-87-1
7784-46-5
56-57-7
7177-48-2
69-65-8
834-28-6
109-69-3
999-81-5
108-94-1
1212-29-9
150-38-9
643-22-1
2164-17-2
85-01-8
5989-27-5
117-81-7
61-82-5
75-65-0
111-42-2
108-78-1
598-55-0
57-83-0
110-86-1
78-42-2
67-72-1
15356-70-4
85-44-9
118-92-3
108-46-3
94-96-2
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No.
47
48
49
50
51
52
53
54
55
56

Chemical Name
Sulfisoxazole
Ethionamide
Curcumin
Benzyl alcohol
Urea
Soduim saccharin
p-Nitrophenol
Sodium xylene sulfonate
Ethyl acrylate
Eugenol

CASRN
127-69-5
536-33-4
458-37-7
100-51-6
57-13-6
128-44-9
100-02-7
1300-72-7
140-88-5
97-53-0

Table B.2: List of Chemicals for Case Study 4.3.2 in Chapter 4
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APPENDIX C
DATASETS - CHAPTER 5

C.1

Case Study 5.3: A Novel Strategy for Development of a Type 1
Hybrid QSAR-QBAR Model
Same dataset used in Case Study 4.3.2 (Table A.2).

C.2

Case Study 5.4: A Novel Strategy for Development of a Type 2
Hybrid QSAR-QBAR Model
Same dataset used in Case Study 4.3.2 (Table A.2).

